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Abstract
M athematical Models of Chemotherapy
John Caxl Panetta
Old Dominion University, 1995
Director: Dr. John A. Adam

Several m athem atical models axe developed to describe the effects of chemother
apy on both cancerous and normal tissue. Each model is defined by either a single
homogeneous equation or a system of heterogeneous equations which describe the
states of the normal and/or cancer cells. Periodic terms are added to model the
effects of the chemotherapy. W hat we obtain are regions, in parameter space (dose
and period), of acceptable drug regimens.
The models take into account various aspects of chemotherapy. These include,
interactions between the cancer and normal tissue, cell specific chemotherapeutic
drug, the use of non-constant parameters to aid in modeling specific chemother
apeutic processes, and drug resistance. By studying the models we can obtain a
better understanding of the dynamics of the chemotherapeutic drugs and how better
to implement them.
The mathematical methods used axe mostly in the area of dynamical systems in
particular Floquet Theory. These methods are used on either a single equation or a
system of periodic ordinary differential equations which model the chemotherapeutic
process. These are reduced to difference equations that describe the state of the
cancer at the beginning of each period. By studying the characteristic multipliers, we
ii
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axe able to determine the bifurcation between successful and unsuccessful regimens,
if existing drug regimens seem reasonable from a mathematical model standpoint,
and suggest ways to better implement the existing chemotherapeutic drugs.

iii
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C hapter 1
In trod u ction
Mathematics gives a good basis for discussing the various effects of cytotoxic drugs
on both cancer and normal tissue. By developing more sophisticated mathematical
models th at more accurately fit known chemotherapeutic responses, we can better
understand how to control the proliferation of cancerous cells. The purpose of this
dissertation is to discuss a variety of mathematical models of cancer chemotherapy
and how they may help clinicians better design drug regimens to effectively control
cancer. There are a variety of factors th at must be taken into account in this process,
including cell kinetics (how different cells grow), chemotherapeutic kinetics (how the
cytotoxic drugs kill cells), chemotherapeutic resistance (how cancer cells develop
resistance to cytotoxic drugs), and effects of chemotherapy on normal tissue such as
bone marrow. The various models th at will be described take into account one or
more of these factors and show some of the mathem atical ideas th a t can be used to
help understand how they function.
The need for these mathematical models is becoming more widely appreciated.
1
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As stated by Birkhead and Gregory [9]:
While certain agreed treatm ent principles seem to have emerged from
empirical experimentation, for some diseases these have failed to produce
any significant improvements in the rate of clinical response, survival, or
cure, and for others, initial progress has not been consolidated. There is
a need, in such cases, to provide insights to help the clinician understand
the reasons for failure and to help him make a rational choice of his next
strategy.
The models described in this dissertation show specific regions of acceptable drug
regimens th at are related to the period in which drugs are delivered and strength of
the dose. This q u a lita tiv e knowledge may help clinicians make choices on how to
better design chemotherapeutic regimens.

1.1

L iterature R eview

The literature on mathematical modeling of cancer chemotherapy is an informative
basis for the present study. To begin with, there are a variety of books and pa
pers th at give an insightful overview of the topic. One of the earliest papers is by
Aroesty et al. [5], They investigate quantitative ways of estimating cell kinetic pa
rameters, such as the growth rate, along with descriptions of the cell cycle which
help in understanding the idea of cycle-specific chemotherapy. In his book, Swan
[61] discusses various models of tumor growth curves including diffusion, stochastic,
and age-structured models (many of these ideas are not covered in this dissertation),
2
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along with topics on cell ecology models and immune response models which will
be a part of this study. Works by Eisen [23], Swan [63, 64], and Knolle [38] also
give descriptions of various models of the cell-cycle and chemotherapy. Skipper [60]
investigates some of the critical variables in combination chemotherapy regimens.
In particular, he studies the average relative dose intensity of drugs administered
in combination, and matching of doses for the largest decay in tum or mass. He
shows many graphs from various experiments with these drug regimens which give
considerable insight as to the effects of combination chemotherapy.
One area in which much research has been carried out is th at of tumor-normal
cell interaction. Much of the work done has involved investigation of the interaction
between the tumor and the immune system. Earlier work by Swan [62] investigates
a m athem atical model of tumor-lymphocyte interaction, and Albert et al. [4], who
present a simple predator-prey model of the tumor-immune system interaction. A
later study by Bellomo and Forni [6] also develops a model of the tumor-immune
system interaction in the form of a predator-prey model. They also include some
simulations and experimental results. A more immunologically-based view of the
interaction can be seen in De Boer et al.

[20, 21], and a more recent work by

Kuznetsov et al. [41] studies the immune response to a tum or using some interesting
nonlineax dynamics. An interesting model by Adam [1] (based on work of Prigogine
and Lefever [59]) studies the one-dimensional spatio-temporal dynamics of cancer
growth with an immune response. Traveling wave solutions are investigated and
lower bounds on wave speeds for wavefronts linking stable tumoral states to unstable
cancer-free states were found.
3
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There also has been a variety of recent literature on more general tumor-host
interaction models. Some early clinical studies by Paschkis et al. [58] and Fisher
and Fisher [25] describe the interaction between hepatic tissue (liver) and tumor
metastases. Both studies indicate th at after a partial hepatectomy not only does the
hepatic tissue start to grow back (because of growth factors produced), but hepatic
metastases also show more rapid growth, thus leading them to believe there is some
positive interaction between the regenerating liver and the cancer cells. More recent
work in the tumor-host interaction has been done by Gatenby [27, 28], who studies
how population ecology models can be applied to tumor-host interaction. Also,
Cornil et al. [16] study the interaction of normal dermal fibroblasts with human
melanoma cells.
Another area of emphasis in the research on chemotherapy modeling is in de
scribing the cell-cycle and the use of cycle-specific chemotherapeutic drugs to take
advantage of the differences in the cancer and normal tissue’s cell-cycle. Some gen
eral references th at discuss the cell-cycle and its importance in chemotherapy are
Eisen [24, 23] and Knolle [38]. More specific models on cycle-specific chemotherapy
are given in Webb [66] which describes a linear two compartment model (both pro
liferating and quiescent cells present) of the chemotherapeutic effects, and in Webb
[67] and Gyllenberg and Webb [33] which describe a non-linear two compartment
model. The basis for these models is developed by Gyllenberg and Webb [32]. Two
other papers which also discuss the toxicity effects of drugs on normal tissue (such
as bone marrow) are Agur et al. [3] and Cojocaru and Agur [13]. Their models ex
amine the reduction in damage to bone marrow by examining the relation between
4
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th e period over which drugs are delivered and the cell-cycle times for the tum or and
bone marrow cells.
Other methods used to help reduce the effects of cytotoxic drugs include the
adm inistration of various types of growth factors, in particular, Hemopoietic growth
factors (HGF’s). Examples of these methods are described in Bhalla et al. [8] and
Demetri [22].
One major disadvantage of many chemotherapeutic regimens is the development
of tum or resistance to the cytotoxic drugs. Some of the original m athem atical re
search done in this area was carried out by Goldie and Coldman [29] who use a
probabilistic model to show how, as the number of tumor cells increases, th e proba
bility of eradicating them before resistant cells take over radically drops. Goldie et
al. [30], also discuss strategies of delivering non-cross-resistant chemotherapy th at
reduce the risk of developing totally resistant tum or cells. Swan [63] investigates
a model of radiotherapeutic resistance with resistant and sensitive cell populations
modeled by first order (linear) kinetics, and compares the advantages and disadvan
tages of periodic and continuous irradiation. Birkhead and Gregory [9] develop a
difference equation model of chemotherapy with drug resistance. They study the
ratio of sensitive tumor cells to total number of tumor cells, which can be found
clinically, and use it to predict tum or size and to estimate model parameters. They
also show the point at which a drug becomes ineffective against a resistant tumor. In
th e case of non-cross-resistant therapy, they discuss patterns of administration and
give conditions for administration strategies. Birkhead et al. [10, 11] and Gregory
et al. [31], also relate the foregoing model to various clinical trials. In addition,
5
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Birkhead et al. [12] develop a linear four compartment differential equation model
which also includes resistance to chemotherapy. Here they model each compartment
of the cell-cycle (sensitive resting and proliferating along with resistant resting and
proliferating) with a linear differential equation instead of a difference equation to
describe more directly the effects of resistance. Another interesting approach to
modeling drug resistance is given by Michelson and Slate [54], who discuss a m ulti
drug resistance as an efflux pump which basically pumps the drugs out of th e cell.
Also, M artin et al. [43, 44] study both single and non-cross-resistant chemotherapy
from an optimization theory standpoint.
Heterogeneous tum or models (i.e. with both sensitive and resistant compart
ments) are another approach to investigating drug resistance. Michelson and Leith
[50] summarize this approach by discussing the various types of tum or heterogene
ity and including much of the theoretical background. A more m athem atical view
of this area can start with Jansson and Revesz [37] whose model is further devel
oped by Michelson et al. [53]. These models describe the competitive interactions
between two different types of tum or cell masses (usually one m utating from the
other). Variations on these topics are continued in Michelson and Leith [46], who
study th e effects of varying the growth rates of the subpopulations; Michelson et
al. [45], who examine stochastic models of subpopulation emergence; and Michelson
and Leith [47], wherein composition of the heterogeneous tum or in the presence of
Mitomycin C (a chemotherapeutic drug) is investigated.
Non-constant parameters are used to increase the generality of the earlier mod
els. Several preliminary mathematical papers which include periodic non-constant
6
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param eters (particularly in logistic and competition environments) are provided by
Cushing [19, 17, 18], Coleman [14], Coleman et al. [15], Hallam and Clark [36], and
Zhien and Hallam [68]. In these papers, the authors start with constant coefficient
systems and incorporate periodically-varying parameters. They also discuss exis
tence of periodic solutions along with conditions needed for these solutions. In works
more related to tum or growth and chemotherapy, Michelson and Leith [46, 48, 49]
and Gyori and Michelson [34] discuss how varying different parameters of existing
models may result in a better fit to tum or growth and chemotherapeutic kinetics.
Recently Michelson and Leith [52] discuss the need for non-constant parameters to
describe the interaction between liver tumors and the liver.

1.2

Topics

This dissertation covers four areas of chemotherapy: (i) tumor-host interaction in the
presence of chemotherapeutic drugs, (ii) cell-specific chemotherapy, (iii) non-constant
parameters, and (iv) drug resistance and heterogeneous tumors. Through the models
developed in these areas, it is hoped to gain a q u a lita tiv e ly better understanding as
to how chemotherapeutic drugs affect the growth dynamics of cancer cells (usually in
term s of the dose and period) and how we may take advantage of this knowledge to
better design chemotherapeutic regimens. In each case the tum or growth is described
by a single or system of differential equations. Added to these equations are the
effects of the chemotherapeutic drug. These are modeled either by a periodic pulsing
function (instant removal of cells) or a piecewise-periodic function (removal over a

7
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period of time) which, is more realistic. In all cases the constraining effects of the
drugs on normal tissue are discussed.

1.2.1

Tumor-Host Interaction

This chapter investigates the tumor-normal cell interaction with the added effects
of periodically-pulsed chemotherapy. The model used in this case is the standard
competition model from population dynamics in which the competition or interaction
in the cancer model occurs between the tum or and normal tissue. Some examples
of this interaction can be, competition for resources, immune response, or growth
factor signals from either the tum or or normal tissue. The model describes param eter
conditions needed to prevent relapse following attem pts to remove the tum or or
tum or metastasis (remote small secondary tumor growth).

1.2.2

Cell-Specific Chemotherapy

In this chapter a linear system of ordinary differential equations is used to discuss
the effects of cell-specific chemotherapy. Cell-specific drugs act primarily on prolif
erating cells. Since tum or tissue has a higher percentage of cells in the proliferating
compartment as compared to most normal tissue, the cell-specific drugs can be an
advantageous method for reducing the tumor mass without overly destroying normal
tissue. Thus this model studies the cell-cycle of the tumor mass, b u t also includes
a constraint equation describing the effects of the drugs on sensitive normal tissue
(such as bone marrow). This model, as the one in chapter 2, uses periodically-pulsed
chemotherapeutic effects to calculate the parameter regions of acceptable dose and
8
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period. It also identifies the optimal period needed for maximal tum or reduction.
Examples are included concerning the use of growth factors and how they may en
hance the cell kill of the chemotherapeutic drugs.
In trying to improve the success of a drug regimen, the clinician can attem pt
to give a larger dose, but because of its effects on the bone marrow, the clinician
may not be able to administer the drug at its optimal period, th at is, the period
which obtains the highest reduction in tum or mass per dose. There axe various
m ethods to alleviate this problem. For example, bone marrow transplants are given
to patients with various types of cancers including Acute Myeloid Leukemia (AML)
after high doses of chemotherapeutic drugs. Another approach is to increase the rate
at which bone marrow reproduces (makes leukocytes, white blood cells). This is done
with various Hemopoietic Growth Factors (HGF). This model shows how, when the
growth rate of bone marrow is increased, we can give the drug at a higher dose at
its optim al period, thus, leading to an overall larger reduction in cancerous tissue.
These methods may seem counter-intuitive, but as we will show, they dramatically
increase the effectiveness of the chemotherapy.

1.2.3

Non-Constant Parameters

The need for non-constant parameters in the previous models is discussed in this
chapter. This includes both effects such as the tum ors ability to m anipulate its
environment with growth factors, the residual effects of drugs, and the use of periodic
chemotherapeutic drugs. For example, as a drug is given, over tim e there will be
toxic buildup in the body, waste from the dead cells, etc. This can be modeled by a
9
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declining carrying capacity for both the normal and tum or cells. Also, a phenomenon
known as the tum or bed effect (TBE) may occur, wherein the tum or, via growth
factors, can increase its carrying capacity. Other examples of the need for non
constant parameters is with the interaction of the liver tum or with the liver, each
has the ability to manipulate the other. The actual dynamics of these interactions
m ay be observed by letting either the growth rate or carrying capacity vary.
In the case of the chemotherapeutic drugs, a logistic differential equation is uti
lized along with both a linear and non-linear system of differential equations with
time-varying periodic parameters. The chemotherapeutic effects are modeled by a
periodic param eter th at modifies the growth rate of the cell tissue. A negative growth
rate represents the detrimental effects of the drugs. Simple criteria are obtained for
th e effects of the chemotherapy.

1.2.4

R esistance and Heterogeneous Tumors

Resistance to various chemotherapeutic drugs is a major cause for failure of chemo
therapeutic regimens. One type of resistance is discussed in chapter 3 where resting
cells are not affected by the cytotoxic drugs. In this chapter, we will study a differ
ent form of resistance, cells become resistant to a drug not because of the phase of
th e cell-cycle th at they are in, but because of physical changes (mutations) caused
by chemotherapeutic drugs to the makeup of the surviving cells. They may also
be inherent a priori and be selected without mutation. There are various types of
resistance and here we will discuss induced or acquired resistance, i.e. resistance
th a t arises as a result of cell mutations induced by the drug. We investigate both
10
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homogeneous and heterogeneous models of resistance. In the case of the homoge
neous model, the cell population is modeled as a whole, not taking into account the
various types of sensitive and resistance cells in the tumor. The heterogeneous tum or
model w ill take these into account. Conditions are developed for either eliminating
the tum or or, in the case where the tumor cannot be eliminated with the specified
regimen, specifying the number of acceptable doses (nadir) th at can be administered
before tum or regrowth due to resistance occurs.

11
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C hapter 2
T um or-H ost Interaction

2.1

In trod u ction

M athematical models of cancer chemotherapy can indicate how micro-environmental
interactions between tum or and normal cells can affect the outcome of the chemother
apy and the ability of a tumor to recur or metastasize. As stated by Knolle [38],
knowing how model parameters affect both the tum or and the normal cells can help
take advantage of kinetic differences between the cells and how they may react to
chemotherapy. Eisen [23] also notes th a t the mathem atics can help “discover ways to
use existing drugs more efficiently,” pointing out th a t even a good drug can appear
useless if administered inappropriately.
One of the earlier steps in developing dose-response curves of the effects of chemo
therapeutic drugs on tum or and normal tissue is discussed by Berenbaum [7]. He
takes a straightforward approach to modeling these effects. He derives basic criteria
for reducing tum or size without overly destroying the normal tissue. These criteria
12
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include administration of the proper dosage and the timing of the dosage. Another
common approach to investigating chemotherapy and its effects on normal tissue is
via optimization theory. Murray [55] models the cell populations with Gompertz
growth and continuous cell-kill and minimizes the tumor population while keeping
normal cells above and toxicity below acceptable levels.
Unfortunately, none of these studies takes into account the possible interaction
between tum or and normal cells (tumors do not grow in an environment isolated
from normal cells; they compete for the available resources and they both develop
growth factors that can affect each other). Adding this feature to the model will
make it more realistic.
This type of interaction does not occur with all forms of cancer. For example,
both brain and lung tumors show little or no interaction with their local environment.
Chemotherapeutic drugs used to eliminate these cancers are in many cases cellspecific (they only kill cells in their growing phase). The tissue local to the tumor
is differentiated (not growing), and as such, it shows little negative effects to the
treatm ent. But, there axe some cases where this type of local interaction is occurring.
This includes tumors in the liver as discussed by Fisher and Fisher [25], Paschkis
et al. [58], and Michelson and Leith [52], along with a variety of other forms of
interactions. For example, Gatenby [27, 28] investigates this tumor-host relationship
considering the interaction to be both the effects of the immune system (for small
tum or mass) and interaction for resources by epithelial (cells lining the internal
and external surfaces) and mesenchymal cells (connective tissue). In particular, he
considers the interaction with a small number of cancer cells. Bellomo and Forni [6]
13
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develop a model of the interactions between the tumor, host, and immune system.
They show th at for small tum or mass, the immune system can retard the growth of
the tumor. It can also be noted that lung tumors do interact with the immune system
response as opposed to other tissue in their local environment. Cornil et al. [16]
address the question of the effects th at adjacent normal tissue such as fibroblasts
have on human melanoma cells. Furthermore, Liotta [42] discusses how various
growth factors produced by both normal and tumor tissues may either suppress or
stim ulate cell growth.
Interestingly, none of these models takes into account the effects of the drug on the
normal tissue. Therefore, we extend the basic models of homogeneous tum or growth
to include chemotherapy and normal cell interaction. The following models examine
the effects of cycle non-specific (a drug th at kills tumor cells at all stages of the cell
cycle) periodically-pulsed chemotherapy in a local tumor-normal cell environment.
Works by Webb [67, 66], Agur et al.[3], Cojocaru and Agur [13], and P an etta and
Adam [57] axe directed to model various types of cycle-specific drug dynamics and
are n o t covered in this chapter. Most importantly, the model in this chapter will
investigate the use of chemotherapy to eliminate either (i) a sm all tumor burden left
after attem pts to remove the main tumor mass have been made, or (ii) a metastasized
tum or mass, and in so doing will provide parameter conditions for tum or relapse.
From these conditions we show that the interaction term along with the normal cell
carrying capacity has a significant effect on the outcome of the therapy. Knowing
these conditions can help in understanding and developing effective drug treatm ents.

14
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2.2

T he M od el

Competition models from population biology have sometimes been used to model cell
interactions. Gatenby [27, 28] investigates models of tumor-normal cell interaction,
while Jansson and Revesz [37], Michelson et al.

[46, 49, 53], and Gyori et al. [34]

examine interaction in heterogeneous tum or populations. Of particular interest is
th e review of heterogeneous tumor populations by Michelson and Leith [50], who
cover a wide variety of topics including the biological implications of the models.
These heterogeneous models will be investigated in §5.2 where we will deal with
tum or resistance. For now, we will study the homogeneous case, i.e. just one tum or
cell population.

As Michelson et al. [48, 49] mention, logistic growth with con

stant parameters is not the best approach in modeling tum or growth. They suggest
th a t models with non-constant parameters th at account for adaptational signals (au
tocrine and paracrine in their models) may better describe these complex dynamics.
However, as a first approximation, the constant case does allow some freedom since
it is not as difficult as other models to analyze in closed form.
We will assume normal and tum or cells interact in the local environment as
described by the competition model from population biology with constant param 
eters. As noted in the introduction, this interaction can be described in various
ways given by Cornil et al. [16], Gatenby [28], and Liotta [42]. It is im portant to
note that in some of these cases the parameters will not be constant, but depend on
various other tumor factors. However, we will only deal with constant parameters,
and let the competition term represent general interactions between tum or and nor-

15
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mal cells. Periodically-pulsed survival conditions axe added to model the effects of
chemotherapy on interacting populations. Kot and Funasaki [39] views a simplified
predator-prey in a pulsed chemostat in a similar way.
We assume th a t (1) the drug is cycle non-specific, (2) there is instantaneous cell
kill by the drug, (3)the parameters are constant, (4) there is no drug build-up in
the environment, and (5) there is no build-up of dead cells.
The basic set of equations that will be studied is:

~

= nXil-XIKi-XiY)

( 2.2. 1)

^

=

r2Y ( l - Y / K 2 - X 2X )

(2.2.2)

X ( n r +) =

F(D)X{nT~)

(2.2.3)

y ( n r +) =

F(D)Y{nT~),

(2.2.4)

The variables and parameters axe:

X : Normal cell biomass.
Y : Tumor cell biomass.
r i , r 2: Growth rates of the normal and tumor cells respectively.

K i , K 2: Carrying capacity of the normal and tumor cells respectively.
Ai, A2:Interactive parameter of normal and tumor cells respectively.

r : Period of dose, r " and r + denote the tim e just before and after a pulse respec
tively.

16
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Figure 2.1: Exponential
F (D ), F (D ) : Survival fraction of normal and tumor cells respectively for a given
dose D. Note that 0 < F ( D ) ,F ( D ) < 1.
Some forms of F(D) and F(D) are given in Berenbaum [7], e.g.:
1. Exponential: F(D ) = e~aD, figure (2.1).
2. Exponential with shoulder: F(D) = 1 —(1 —e~aDy , 0 > 0, figure (2.2).
3. Hyperbolic: F ( D ) =

7, 7 > 0, figure (2.3).

See Knolle [38, pp. 89-90] for indications of how the exponential dose-response curve
is formulated.

2.3

R ecu rrence in th e A b sen ce o f C h em oth erap y

In the absence of chemotherapy, the two periodic conditions (2.2.3,2.2.4) are removed
and the problem reduces to the ordinary competition model. We must ask this
17
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Figure 2.2: Exponential with shoulder
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question: is the tumor-free case, ( i f i , 0), stable to small perturbations (compared to
the normal cell mass)? In other words, can a small amount of tum or mass (perhaps
remaining after surgery) survive or will the patient remain in the disease-free state?
Linearizing about this equilibrium ( X = K \ + tu and Y = 0 + ev where e is small
compared to K \) we obtain:

(

v!

\

/

-r 1

—XiriKi

\ (

u

\
{2.3.5)

0

^ ( 1 — X2K \ )

\ v !

From (2.3.5) it may be seen th at the tumor population can recur if K i \ 2 < 1 (the
eigenvalue 1 —X2K i is positive). For more information on the relevant mathematical
analysis see W altman [65]. The term K i X2 will be referred to as competitive pressure.
Note th a t a similar result, derived differently, can also be found in Gatenby [28]. It
can be seen th at damaged normal tissue environment (reduced K \) will be more
susceptible to tumor recurrence along with poor competition for resources among
th e normal cells (small A2). If the parameters are non-constant, controlled by the
growth factor signaling as in Michelson et al. [48, 49], then recurrence can be more
difficult to visualize, but is also more realistic.

2.4

R ecu rrence w ith P u lsed C h em oth erap y

Once chemotherapy is incorporated, it is very im portant to examine the effects it
has, not only on the tum or cells, but also on normal cells. Otherwise, the regimen to
destroy the tum or might also overly destroy the normal cells, and thus the patient.
A commonly acceptable reduction in total normal tissue mass is about 50% of its
19
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carrying capacity. So, first let us identify some basic conditions th at must be placed
on the therapy in the presence of normal cells only, and then examine the drugs
effects on the tumor cells.

2.4.1

Norm al Cell Growth

In the absence of any tum or cells, the system reduces to:

^

=

X { n r +) =

n X il-X /K ,)

(2.4.6)

F{D)X{nr~ ).

(2.4.7)

The solution which holds between pulses, which is the standard solution to the
logistic differential equation, is:

X{t] =

+

(-* ) ;

nT < * < ( ' * + ^

(2 -4 ' 8>

where X nr = X ( n r ) . At the beginning of each successive pulse, the solution, using
the pulsing condition (2.4.7), is:

x^

f ^ x „ H k : X ) « -* •

( 2 -4 - 9 )

Equation (2.4.9) has two equilibrium points:
X* = 0
u

X*3 = K ^ ( D ) ~ e nT) .
s

(1 - e~TlT)

(2.4.10)
v

'

Note th a t for X* to exist and to be stable, F { D ) > e~TlT. Otherwise X* is th e only
equilibrium th at exists, and it is stable. Since F(D) > e-riT allows even 99% of the
normal cells to be killed and still have survival, then th a t condition in most cases
is not acceptable and must be made more rigid. According to Berenbaum [7], an
20
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acceptable level of cell kill for normal cells is about half the original state. This, in
general, depends upon the type of normal cells th at are being identified. Some can
survive much larger cell kills than others. But to avoid specifying any particular
type at this point, and to keep the model flexible, we will require X* > aK\, where
a is the percentage of acceptable reduction from the steady state for normal cells.
Using the above information, it can be seen th at the survival fraction m ust be:

F(D) > a + e“riT(l - a)

(2.4.11)

for there to be at least a% of the normal cells left. Substituting X* into (2.4.8) we
get the steady-state periodic solution:

*•(*) = TF™
----- 7*— T 5
F( D) - e _riT-|-(l - F ( D ) ) e - ri(t~nT)

2.4.2

nr < t < (n + 1)r.

(2.4.12)

Recurrence of the Tumor

Now, examine the recurrence of a small amount of tumor cells, Y = 0 + eu (v is 0(1),
and represents the tumor mass). As suggested earlier, this can be an 0(e) amount of
tum or mass left after surgery. The question to be asked is, can the tum or continue
to grow, or is the chemotherapy strong enough to eradicate it while maintaining the
normal tissue above some acceptable level? To answer this, we linearize the original
system about (Xa(t),0), and study the stability of the tumor mass. If the linear
system is unstable in u, then the tumor can recur; otherwise the (X ,(f), 0 ) state is
stable and the chemotherapy prevents tumor recurrence. Letting X = X s(t) + eu,
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the linear system is:

/

u'

\

(

'n (l-2 ^ 1 )

\ /

-riAA(i)

u

\
(2.4.13)

o

\ V /

^2(1 —A2X 3(t)) j

\ v J

Thus, the stability of v can be determined by v' = r 2(l —\ 2 X s(t))v. Since X s(t) is
periodic with period r , integrate over one period to get:

n+l)T = F(D )vnreT2f n r +1)T

(2.4.14)

or in a more useful form:

P V m < >
V(n+1)T = VnTl<
{JJ)e

f (n+1)T Xs(t)dt .
zJnr

e r2 r - r 2 A2

(2.4.15)

Calculating the above integral and simplifying, we get:
er 2 T

ln { « ( » + i) r = a ( D

) e

r2A2iCi

^

ri

'r 2 W

-

(2.4.16)

or:
F(D)e'TIT
^(71+ 1)7

1*2A0 X 1

.F(D)

ri

(2.4.17)

eT^ 2KlT

If the characteristic multiplier of equation (2.4.17) (the term in brackets) is less then
one, the tum or will regress. Thus, to prevent recurrence:

F(D) < F ( D ) a ^ r Le~TT2^1~X2Kl\

(2.4.18)

Note th at A2.Ki < 1, since this is the condition for tum or survival without drugtherapy. In other words, if A2.£fi > 1 then there is no need for any chemotherapy
since the tum or is killed by competition with other cells (see § 2.3). To make it
difficult for the tumor to recur, the right hand side of (2.4.18) must be large, close to
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one. Therefore, either an increase in r 2 (tum or regrowth rate) or r (period between
treatm ents) will increase the ability of the tum or to recur, and an increase in ri
(normal cell regrowth rate) or X2 K 1 (competitive pressure) will decrease the ability
of the tum or to recur.
If F (D ) = e~aiD and F(D) = e~a2D then the conditions which prevent the tumor
from recurring are:

B
D

P '4-19)
< (—a i )-1 In (a + e-riT(l —a))

(2.4.20)

where the first condition is derived from equation (2.4.18) and the second comes
from (2.4.11). Note th at both of these equations are affected by normal cell param
eters ( if i, A2, r%, a i, a). For example, as the competitive pressure A2-K1 increases,
less of a dose is needed to prevent recurrence. For there to exist a region of accept
able dose and period, the graph of equation (2.4.20) must be above th at of equa
tion (2.4.19) for some region. For this to happen (noting th at Dose=0 at r = 0), the
slope of equation (2.4.20) at r = 0 must be larger then th at of equation (2.4.19). To
satisfy this, the following condition is needed:
>

(2 4 21)

r i( l - a )
From this condition, we can see (as might be expected) th at for the treatm ent to
be effective, the chemotherapeutic drug m ust have more of an effect on th e tumor
cells then on the normal cells, unless the normal cells are able to grow back faster
(ri > r 2).
23
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Figure 2.4: Dose-Response Curve: Dose vs. Period

Figure 2.5: Dose-Response Curve: Dose vs. Period vs. Host Survival (a)
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Figure 2.4 gives one example of a region of acceptable dose and period. A dose
and period chosen above the line, “Tumor Condition” , and below the curve, “Normal
Condition” will prevent the tumor from recurring and keep the normal cells above
the specified level a. This also shows graphically the need for condition (2.4.21).
Figure 2.5 gives a similar view with varying host survival (a). Here, we want to
choose a dose and period above the plane and below the curved surface. It can be
seen th at as the condition on host survival (a) is increased, the region for successful
treatm ent is decreased. In fact, Figure 2.6 shows where the graphs in Figure 2.5
cross. This forms the boundary between where a successful region exists and does
not. Figure 2.7 shows the effect of varying A2A i. As predicted, for small values of
\ 2K i , it will take a larger dose to prevent tum or recurrence. This can be interpreted
as when the competitive pressure (A2A i) decreases, the drug therapy will need to be
made more effective to continue to prevent recurrence. And if there is no competition
at all, i.e. Ai)2 = 0 then the drug therapy must be able to eliminate the tum or alone.

2.5

D iscu ssion and C onclusions

Since tum or cells are n o t isolated from their micro-environment, but are constantly
competing with the host for resources, the models discussed here, which include
tumor-normal cell interaction, are a step toward better describing chemotherapeutic
effects. However, few researchers who have modeled chemotherapy have studied the
effects the drugs have on normal tissue, or the effects of the normal tissue on the
tumor. Since this first effect is possibly the most im portant constraint on the use
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of chemotherapeutic drugs, it m u s t be a part of any model th a t will accurately
describe the interplay of the system.
The models in this chapter indicate th a t there are definite param eter regions
of acceptable and unacceptable chemotherapeutic regimens, giving us a qualitative
idea of how each param eter affects tum or recurrence. In particular, we show how
th e competitive pressure (A2-A1) can control and even prevent tum or growth and
recurrence. Also, we show how certain doses (D ) and periods (r) can lead to tumor
regrowth.
Gatenby [27] points out th at when therapy is withdrawn, th e tum or will just
grow back to its original size unless it is totally destroyed or the characteristics of
th e system have changed (by changing parameters through a critical point). As seen
in this model, one of these changes can be an increase in A2A 1 through th e critical
value of one which will make it impossible for the tum or to recur. A relevant topic
in this regard is th a t of growth factors as discussed by Michelson et al. [48, 49]. In
particular, the paracrine path, which can be described mathem atically as th e varying
of the carrying capacity Ki by tum or growth factors, can change the recurrence
condition significantly. Additionally, Gatenby [27] discusses how damage to the
local tissue (normal cells) and devascularization (the preventing of blood vessels
from growing into the tumor) can help the tum or mass emerge. T hat is, the carrying
capacity is reduced because of dead cell buildup or increased levels of toxic drugs,
thus making it easier for the tum or to emerge. These ideas give rise to the need for
models with non-constant parameters.
Even though further work will be required to address the simplifications in these
27
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models, they do provide a useful initial indication of th e dynamics of tum or recur
rence. The parameter conditions arising from these models define our expectations
for the effective chemotherapeutic treatm ent of tum or recurrence, giving us more
insight into how to administer the drugs more efficiently.
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C hapter 3
C ell-Specific C hem otherapy

3.1

In trod u ction

Many chemotherapeutic drugs axe cell-specific: they only destroy specific types of
cells in specific phases of their cycle (usually proliferating cells). Some examples of
these types of drugs axe Cytosine Arabinoside (Ara-C), 5-fluorouracil and Prednisone
which work in the G\ and S phase of the cell-cycle and Vincristine and Bleomycin
which work in the M phase of the cell-cycle. Most of the clinically-used methods
of delivering chemotherapy have been developed empirically, and as stated by Birkhead et al. [12]: “In the absence of more effective new drugs there is an increasing
need to define better treatm ent strategies with existing agents.” The object of the
model in this chapter is to give some qualitative ideas on how to better administer
cell-specific chemotherapy. This model is not meant to dictate to the clinician which
regimens of therapy axe appropriate, for each individual patient is different and re
quires quantitatively different treatments. In fact, in most cases even approximate
29
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ranges for parameters and drug effects are not known (R. Perry, private communi
cation). But, it is hoped th at this model will give some q u a lita tiv e ideas on how
to better implement cell-specific therapy.
Some of the more recent work done with mathematical models of cell-specific
chemotherapy are by Webb [66 , 67]. He develops both linear and non-linear models
of cell-specific chemotherapy. In the case of the linear model, the advantages of
periods of dose with shorter duration are investigated. Another work of interest is
by Birkhead et al. [12] in which a four-compartment linear system is developed to
model the cycling, resistant, and resting cells. Their results are limited to a few
numerical calculations on four specific types of treatments. Swan [64] also examines
cell-specific chemotherapy in his review article. In particular he concentrates on agestructured models which take into account the age of the cells in each compartment
of the cell cycle. He also studies an age-structured chemotherapeutic model of acute
myeloid leukemia AML. Eisen and Schiller [24] study a two-compartment model
of tum or growth with non-constant growth rate. In addition, Kuzma et al. [40]
examine a model with exponential growth for the tum or and both immediate and
delayed effects of drugs. In their model they study a variety of results including the
number of doses needed for a specific tum or reduction, the minimum initial dose
needed for tumor reduction, and some toxicity effects. The issue not discussed in
any of these articles is the effects of the drugs on normal tissue. An interesting
approach to the problem of toxicity to bone marrow and other sensitive tissues
has been investigated by Agur et al. [3] and Cojocaru and Agur [13] (this adds age
structure to the previous). They develop criteria to maximize the tum or cell kill while
30
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minimizing bone marrow damage. They accomplish this by examining the relation
between the period in which the drugs are delivered and the cell-cycle tim e for the
tum or and bone marrow cells. The idea is to administer the chemotherapeutic drug
when the cancer cells are in a more vulnerable growth phase and the bone marrow is
in a less vulnerable stage. These two articles also differ from the other above articles
in th at they only consider cells in the growth phase of the cell cycle, i.e. they do not
consider the resting stage ((?o).
The model in this chapter will extend the linear models described in Webb [66],
Birkhead et al. [12] and Eisen and Schiller [24] by adding both pulsed and piecewisecontinuous chemotherapy, and by examining th e effects of the cell-specific drug on the
normal tissue. The tissues that will concern us in particular are the fast proliferating
tissues such as bone marrow or those comprising the gastrointestinal tract. From
this model we will identify parameter ranges, in terms of dose and period, needed to
prevent further growth of the tumor.
One chemotherapeutic regimen used, as stated by Birkhead et al. [12], is “the
maximally-tolerated dose is given as frequently as the rate of bone marrow recov
ery permits.” Using the model developed in this chapter, we will investigate this
chemotherapeutic regimen. The model will show for a given dose what the optimal
period is to have maximal tumor cell kill. We will show th at in some cases the model
confirms Birkhead’s regimen and in others this is not the “best” way to deliver the
chemotherapeutic drugs.
Another method of increasing the ability of cell-specific drugs to destroy the
tum or (while not overly destroying normal tissue) is to provide growth factors to
31
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the tum or and/or normal tissue. One such type of growth factor used in treating
breast cancer is exogenous estrogen. This increases the tum or cell proliferation to
make the tum or more susceptible to the chemotherapeutic drugs. Another class of
growth factors used axe the hemopoietic growth factors HGF such as granulocyte
colony-stimulating factor G-CSF, granulocyte-macrophage colony-stimulating factor
GM-CSF, and interleukin-3 IL-3. These growth factors are used in AML to increase
the percentage of cells in the S phase (the phase which many chemotherapeutic
drugs are most active) and in breast cancer to increase the levels of circulating
leukocytes (white blood cells). Bhalla et al. [8] states th at G-CSF, GM-CSF, and
IL-3 increase about two to four times the number of AML blasts in the S phase
while Demetri [22] states th at these HGF’s allow larger doses of chemotherapy to
be safely given because of the increased circulating leukocytes. This model will
take into account these growth factors, by varying appropriate parameters such as
cell growth rates, and show how they increase the effectiveness of the cell-specific
chemotherapeutic agents.

3.2

M od el

A two-dimensional linear differential equation with periodically pulsed chemotherapy
is used to describe the effects of chemotherapy on a tum or. The basic model is similar
to the two-compartment model described in Eisen and Schiller [24], and to the model
given in Birkhead et al. [12] who include resistant compartments for both the cycling
and non-cycling cells, thus increasing the dimension of their model to four. Both
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examine similax models to describe basic tumor growth. However, the model in this
chapter not only identifies the chemotherapeutic effects more explicitly, but more
im portantly it models the effects of the drugs on normal tissue.
Some basic assumptions are made to keep the model tractable. Firstly, we only
study a linear system (first-order kinetics) to describe tum or growth. This limits the
model to either exponential growth or decay without any intermediate equilibrium.
Nevertheless, this is an acceptable first approach since a successful chemotherapeutic
regimen will prevent the tum or from growing near its carrying capacity, so th at the
non-linear effects of logistic or Gompertz growth will be minimal, allowing us to
use the simpler model. Birkhead et al. [9, 12] and Kuzma et al. [40] also utilize
exponential tum or growth between doses. Secondly, all the parameters are held
constant (except for the case of growth factors). In their model Eisen and Schiller [24]
incorporate non-constant growth, but we will avoid this and focus more on the
chemotherapeutic aspects of the model. Thirdly, we ignore spatial or age effects.
T hat is, the resources and chemotherapeutic drugs are assumed to reach all cells
equally, and cells of all ages axe affected uniformly (however, this model does take
into account natural cell decay). Fourthly, even though the cycling compartment
actually has four sub-compaxtments or phases including the gap period (Gh), the
synthetic period (S'), the second gap period (G 2), and mitosis (M ) (see figure (3.1)),
our model combines these four sub-compaxtments of the cycling phase into one to
yield a two-compartment model containing a cycling and a resting compartment.
Finally, even though cell-specific drugs still have some effect on resting cells (though
the faster proliferating cells will definitely be more affected), we assume th at resting
33
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cells (Go) are not affected by the drugs. It is important to note th at making the
system more complex does not necessarily make it more useful. The simpler system
allows us to view many interesting features of cell-specific chemotherapy without
the undue mathematical complexity. Even with these assumptions, the model still
shows many interesting dynamics and can address some of the m ajor questions of
chemotherapy such as: will the tum or grow or decay, how will the m ajor parameters
(dose and period) affect the outcome, and what is the optimal regimen to deliver the
drugs.

3.2.1 Two-Com partm ent M odel
The form of the linear two-compartment model as described in figure (3.2) is:
/

\

, i \
dx
dt
dx•}.
dt J

___

a — {1 — 7]
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' /
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\
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Figure 3.2: Two-Compartment Diagram
where the parameters axe all constant, positive, and defined as follows: a , cycling
cells growth rate; //, rate which cycling cells become non-cycling;

77 ,

natural decay

of cycling cells; /3, rate which non-cycling cells become cycling; 7 , natural decay of
non-cycling cells (optional). The elements of the vector (xi,X 2 )t = x represents the
cycling and non-cycling tumor cell mass respectively. We will assume th a t a > rj
(positive net growth rate), i.e. in the absence of chemotherapy, the tum or will grow
without bound.

We will also assume th at a — fi — rj < 0, i.e. a large number

of cells move to the non-cycling or quiescent compartment. Birkhead et al. [12]
suggest th at only about 20% of the tum or cells axe cycling. To simplify the form, let
a = —(a —/i —77 ) and 7 = 0 . Thus, the generalized lineax system is:

(
dx
dt

—a

fd

\
x
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(3.2.2)

where a,/3,fi> 0. Birkhead et al. [12] give one set of parameter values from breast
cancer data that fit the above conditions, namely, a = 0.5, /jl = 0.218, rj = 0.477, (3 —
0.05.
Now we examine the periodic chemotherapeutic conditions. In this model of
cell-specific chemotherapy, we assume the drugs only affect the cycling cells, x\. We
will model the chemotherapeutic effects with pulsed chemotherapy as in chapter 2 .
Again, this describes a constant instantaneous cell kill at each period of dose. The
pulsing periodic condition is:

(

\

o

m

Znr+ =

(3.2.3)

where 0 < f( D ) < 1 is the survival fraction (which is a decreasing function of dose
D), and r is the period between doses. r + refers to the instant after the drug is given
and t ~ refers to the instant prior to the dose of the drug. Specific forms of f { D )
can be found in Panetta [56]. Also, Birkhead et al. [12] examine 0.05 < f ( D ) < 0.4.

3.2.2

Normal Cells

One of the major drawbacks of chemotherapy is th at it also affects normal cell tissue.
In the case of cell-specific chemotherapy, tissue like bone marrow which proliferates
rapidly will be strongly affected by the drug and this will have to be taken into
account when developing a chemotherapeutic regimen. There axe a variety of ways
to approach this problem. P anetta [56] examines the interaction between normal
and tum or tissue and the effects of cell-non-specific drugs on them. In many cases,
such as with bone marrow, there is probably no interaction with the tumor, but the
36
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drugs still affect it. This is the case th at we will examine in the present model. If
we assume th a t the normal tissue has limited growth between pulses of the drug
as described in equation 3.2.4, then a suitable linear constraint equation for pulsed
therapy is:

y = 8(K -y),

ynT+ = f ( D ) y nT~, n r < t < ( n + l)r,

(3.2.4)

where 8 is the growth rate, K is the carrying capacity, f ( D ) is the survival fraction
for the normal tissue and f ( D ) > f( D ) . This inequality means th a t the drug affects
the tum or cells more than the normal cells. Logistic growth can also be used to model
the growth of the normal tissue though, in this case, the equation is non-linear. The
form of the logistic constraint equation for pulsed therapy is:

y = Sy(l - -|r), ?/nT+ = f ( D ) y wr- n r < t < ( n + 1)t.

(3.2.5)

The logistic equation with pulsing is solved in section 2.4.1 and in Panetta [56]; the
solution to equation (3.2.4) is similar in form and is given in the following section.

3.3

P u lsed Case

The first step in analyzing model (3.2.2) with pulsing condition (3.2.3) and constraint
equation (3.2.5) is to develop solutions for (3.2.2) and (3.2.5) over one period n r <
t < (n + l) r . Once this is accomplished we can then apply th e pulsing condition to
arrive at a linear system of difference equations (sometimes referred to as the first
return map or Poincare map, see Hale and Kogak [35]) th at will describe the growth
of the tum or a t each pulse.
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3.3.1

Norm al Tissue

First, consider the linear case of limited normal tissue growth. Solving equation (3.2.4)
yields the difference equation:

y(n+i)r = f ( D ) { K + (ynT - K)e~Sr}.

(3.3.6)

This has a unique equilibrium:

*• -

•

( 3 -3 -7 )

As in section 2.4.1, we require y* > u>K, where w (0< u> < 1) is the acceptable
fractional kill of the carrying capacity K . Hence, the constraint for limited linear
growth on the chemotherapeutic regimen in terms of dose and period is:
u < f(D )(l - , r » )
- 1 - f { D ) e - ‘r

( 3 .3 .8 )
'

Now, in a similar manner, the logistic constraint is also solved. As in section
2.4.1, solving equation (3.2.5) yields the difference equation:

+

!/(„«). =

(3'3 J )

which has two equilibrium points:
„
* K ( f ( D ) — e~Sr)
y*u = 0 y : =
[\ _ Je. Sr
■

(3.3.10)

Thus, the constraint on the chemotherapeutic regimen in terms of dose and period
is:

"^f V

- X

T-

(3-3-n)
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In both cases, the cell-specific chemotherapeutic drugs have less effect on these
tissues, primarily since a much higher percentage of normal tissue is in th e resting
phase, though this is not the case with bone marrow. Therefore /( D ) > /( D ) since
more normal than cancerous tissue survives each dose.

3.3.2

Effects on Tumor

First, examine equation (3.2.2). Hale and Kogak [35, chapter 8] provide a good
account of the general solutions to linear systems such as this. The form of the
solution given by many elementary ordinary differential equation texts is x(t) =
+ c2^2e>l2^_nT^ where the Xi's axe the eigenvalues, and & 's are th e cor
responding eigenvectors to the coefficient m atrix of (3.2.2). This solution is defined
on the interval n r < t < (n + l) r . By our choice of signs of th e param eters in
the coefficient m atrix, one eigenvalue must be positive (e.g. Ai), with eigenvector H
in the first quadrant. Thus, the tum or will grow in the absence of chemotherapy.
The other eigenvalue must be negative. This can be observed by calculating the
eigenvalues directly. They are:
_

(3 3 12)

4(a - it)
Since a,

> 0 and a > 7 7 , then a —(j, < 0. So, equation (3.3.12) has one positive

and one negative eigenvalue. It will be more convenient for us to write the solution
in the form:
/

w

,

e A i( i- n r )

q

\
P

2(t) = P
0

x nT, n r < t < ( n + l)T,

(3.3.13)

e * 2 (i-n r )
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where

(3.3.14)

P = & 16)

is th e transformation, m atrix of eigenvectors and xnT is the tum or mass at the begin
ning of the nth period.
Now, adding pulsing condition (3.2.3), the following difference equation describes
the tum or mass just after each pulse of drug:

(

\
eAlT

®(n+l)r =

(

0

-l

P
eAjT

0

\

\
m

v

o
0

(3.3.15)

1

To determine whether the system is growing or decaying, the eigenvalues or charac
teristic multipliers of the characteristic matrix
/
eAlT

0
3 -1

0

eAaT

\
m

o
0

(3.3.16)

1

of equation (3.3.15) need to be investigated. We will define the eigenvalues of ma
trix (3.3.16) as A,; these can be found in terms of f ( D ) , r , and A; (fixed). If
15a x (|A i(/(D ),r)|) < 1

(3.3.17)

then the chemotherapeutic regimen will destroy the tumor; otherwise the tumor will
grow. Therefore, we axe interested in finding the bifurcation curve which separates
growth from decay, i.e.
gax (|A i(/(T > ),r)|) = 1,

(3.3.18)

in term s of the survival fraction /(£>) (or dose) and period r .
Also, in region (3.3.17), there axe some regimens th at axe more effective than
others in destroying the tumor (e.g. by choosing th e period which minimizes the
40
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maximum value of |Aj|for a given dose). The most effective chemotherapeutic regi
men is therefore defined as

mm
ri n ( g a x (|A i(/(D ),r) |))
T

(3.3.19)

for each fixed f{D ). However, this does not take into account the effect of the drugs
on the normal tissue. We must consider this expression along with inequalities (3.3.8)
or (3.3.11) when developing effective chemotherapeutic regimens. This is carried out
in the next section.
Now observe th a t the m atrix (3.3.16) can be expressed in the form:
( (£ii£ 22eAlT - fo f c ie ^ ) f ( D )
det(P)

- £ n £ i 2(eAlT - eA*T)

^
(3.3.20)

^

(£u£ 22eA2T —£i2£2ieAlT) t

£2i£ 22(eAlT —eA2T)/(D )

Denoting this characteristic m atrix (3.3.20) C M , its eigenvalues are:
_
trace(CM) ± J ( t r a c e ( C M ))2 —det(CM)
\----- >1--------- ^----- '.
Ai ( f ( D ) , r ) = -------^------L - V i

(3.3.21)

Calculating the det(CM) and trace(CM), we obtain:

det(CM) = f { D ) e ^ +x^ T > 0

(3.3.22)

and
trace(CM) = (gf{D) - h)ex' r - (h f { D ) - g)ex*r > 0

(3.3.23)

where
£n£22
=
9 = d e t ( P y, and h ~
det{P)'

(3.3.24)

Because of the signs of the coefficient m atrix of equation (3.2.2) £11, 6.2 > 0 and
£21,62 have opposite signs. Thus, it can be observed th at both trace (CM) and
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d e t ( C M ) axe positive because of the signs of the elements of the eigenvectors. There
fore max; (|A;(/(£>), r)|) = A i(/(D ), r). By the correct choice of the dose and period
we axe able to force Ax(/(£>), r ) < 1, thus eliminating the tumor.

3.3.3

R esults for Pulsed Therapy

First, we will examine the bifurcation diagram of the model with respect to survival
fraction f { D ) and period r . That is, we investigate the graph of the bifurcation
equation (3.3.18) with i = 1 and the constraint equation (3.3.8) or (3.3.11). Using
the parameters afi/3 listed in § 3.2.1, u> = 0.5, and 8 = 0.1 along with the logistic
constraint equation (3.3.11), we obtain figure 3.3 for f ( D ) = 2/(13) (normal tissue
survives twice as well as tum or tissue) and figure 3.4 for f ( D ) = 4/(13) (normal tissue
survives four times as well as tumor tissue). The tumor condition curve represents
th e bifurcation from tum or reduction to tum or growth and the normal condition
curve represents the bifurcation from overdestruction of normal tissue to acceptable
normal cell loss.

From these curves we can see the area, in param eter space, of

acceptable dose and period th at will eliminate the cancer cells while maintaining the
normal cells at a level of at least half their carrying capacity.
As can be seen, this region is not small, so given th at we have a prescribed
dose to administer, what is the optimal period in which to deliver th at dose? To
answer this question we will minimize A i(/(13),r) with respect to r. One might
assume th a t for a given survival fraction the optimal frequency to administer the
drug (without considering normal tissue) would be continuously. But, investigating
equation (3.3.19), it can be seen that the optimal period is actually greater than r « 0
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Figure 3.3: Bifurcation Diagram: f ( D ) = 2f{ D )
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Figure 3.4: Bifurcation Diagram: / (D) = 4 /(D )
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Figure 3.5: A i(/(D ),r) vs. r , f ( D ) = 0.25
(continuously delivering drugs). This is because by allowing some tim e between each
dose, more resting cells axe perm itted to move to the cycling compartment, and so
there are more cycling cells to be killed when the next dose is given. Also, it should
be noted th a t giving the drugs at a very rapid rate will destroy the normal tissue
too rapidly! Thus, a calculation of th e optimal period is extremely practical. For
example, with f ( D ) = 0.25, the optimal period to deliver the drug is r

8 (i.e. this

is the minAi with respect to r: see figure 3.5), while an acceptable period (Ai < 1)
ranges over the large interval 0 < r < 40. In general, the optimal period is shown in
figure 3.6 for 0 < f ( D ) < 0.9. As can be seen, for more effective drugs (i.e. smaller
/(£ ))) the optimal periods axe laxger than for less effective ones, thus allowing the
normal tissue more tim e to recover.
Now, consider the chemotherapeutic regimen stated by Birkhead et al. [12]. That
is, “the maximally-tolerated dose is given as frequently as the rate of bone maxrow
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recovery perm its.” Before seeing if our model agrees with, this protocol we need
to consider what is implied by this regimen. There axe two possibilities; either to
administer the drug rapidly without using a strong dose, or to allow higher doses but
administering them less frequently. By noting the bifurcation diagram for / ( D ) =
2/(D ) (figure 3.3) and the optimal period graph (figure 3.6), we observe th a t the
calculated optimal period is a better regimen if a smaller dose (survival fraction
/(D ) > 0.3) is given more frequently; Birkhead’s regimen is better if the opposite
holds true. This can be observed in figure 3.7 by noting where the optimal period
curve and the normal condition curve (S = 0.1) cross. If the survival fraction is to
the right of this intersection then the optimal period is best, and if it is to the left
then it is not. Of course the parameters chosen are just one possible acceptable set;
thus, as stated above this is merely a qualitative examination of the problem.
In many cases the clinician would prefer to give a larger dose than is acceptable
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by conventional methods. The problem, as can be seen in figure 3.7, is th a t large
doses (small f( D ) ) must be administered over a larger than optimal period to prevent
overdestruction of the normal tissue. In the case of reduced leukocyte production
because of damage to the bone marrow, HGF’s axe used to help counteract this prob
lem by increasing leukocyte production. This process is modeled mathematically by
increasing the growth rate, 6, of the normal tissue equation (either equation 3.2.4
or 3.2.5). As can be seen from figure 3.7, a higher growth rate for the normal tis
sue increases the region of acceptable drug regimens, thus allowing higher doses of
chemotherapeutic drugs to be given at their optimal period. If r = 20 (the best pe
riod without growth factors, 6 = 0.1) and f ( D ) = 0.275, then there is approximately
a 65% reduction in tumor mass. But, if growth factors axe given (6 = 0.5) then the
optimal period of r = 7.25 can be used and there is approximately a 82% reduction
in tum or mass, which is a 27% increase in tum or reduction over the non-optimal
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Figure 3.8: r = 20, f ( D ) = 0.275
period! Figures 3.8 and 3.9 show the phase planes (resting vs. proliferating) for each
case. Observing figure 3.8 we can see why the non-optimal period does not have as
large a cell kill as the optimal case. The graph shows th a t the proliferating cancer
cells are able to start regrowth before the next dose is given. Thus, this regimen is
not optimal since the dose is too large.
Another use of HGF’s is with AML. They are used to increase the ratio of pro
liferating to resting cells, thus increasing the cell-kill of a cell-specific drug. This is
modeled by an increase in the parameter /3, which is the rate at which resting cells
become proliferating. One question to be asked is: how does an increase in /3 affect
the maximum eigenvalue of the characteristic polynomial? Examining the deriva
tive of Ax with respect to /3, it can be seen th at Ai(/3) is a decreasing function for
/? > 0. Thus, by increasing the rate at which resting cells become proliferating, the
characteristic multiplier Ai decreases, which means there is a larger cell-kill. This

47

R eproduced w ith perm ission o f the copyright owner. Further reproduction prohibited w itho ut perm ission.

60
55
50
45
40
35
30
25
20

15
10

0

2

4

6

8

P r o life r a tin g

10

12

14

16

C e lia

Figure 3.9: r = 7.25, f ( D ) - 0.275
can be seen in figure 3.5. Further, we note th at the optimal period decreases as /?
is increased (see figure 3.6). This can be understood as the cells are moving into
th e cycling compartment faster so the optimal period is arrived at faster. The most
im portant feature is th a t by introducing a growth factor the same number of doses
can have a larger overall effect on the AML. This can be seen in figures 3.10 and
3.11. W ith the previously stated parameters it is calculated th a t fifteen doses of a
drug with AML survival fraction of f ( D ) = 0.25, period of r = 8 and /3 = 0.05 will
reduce the amount of AML by approximately 86%, while reducing it by 97% with
/3 = 0.1. In this case there is a 13% increase in tumor reduction.

3.4

D iscu ssion

For chemotherapeutic drugs to be useful they must be given to the patient at an
appropriate interval with an effective dose. The clinician m ust also take into account
48
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49

R eproduced w ith perm ission o f the copyright owner. Further reproduction prohibited w itho ut perm ission.

the effects of the drugs on the normal tissue. Otherwise, a given drug regimen might
eliminate the tum or but also destroy the normal tissue, or even have no detrimental
effect at all upon the tumor. Thus fax, few of the mathematically constructed models
have incorporated these features, and most drug protocols are developed empirically.
It is our hope th at this model gives some indication of how to better administer the
drugs in order to more effectively destroy the cancerous cells.
The most basic question that can be asked about a chemotherapeutic regimen
is, how much is enough and how much is to o much? We have shown using the
characteristic multipliers of the Poincare maps th at there is a bifurcation or boundary
(in term s of survival fraction and period), separating regimens th a t will and will not
eliminate the tumor mass. As noted earlier, this is only intended to be an essentially
qualitative study, and quantitative details will of course vary from patient to patient.
Clearly a bifurcation diagram is not sufficient to develop a good chemotherapeutic
regimen because it includes modalities like continuously giving a very large dose of
the drug. Obviously this will eliminate the tum or mass, b u t it will also kill the
patient! Thus the use of the constraint equation th at models the effects of the drugs
on the normal tissues must be included.
However, with the constraint equation added, there is still a wide range of ac
ceptable drug regimens. Thus we look for the optimal regimen. In doing this we
have shown th at the best drug protocol is not delivering the drug as often as possi
ble and as strongly as possible, but rather there exists an optimal period and dose.
Because of the constraint of normal tissue survival, this is not always possible with
each dose (survival fraction). That is, for stronger doses, the period of delivery must
50

R eproduced w ith perm ission o f the copyright owner. Further reproduction prohibited w itho ut perm ission.

be broadened at non-optimal periods to prevent overly destroying the normal tissue,
or a weaker dose must be administered.
Growth factors increasingly are being used to help cell-specific chemotherapeutic
drugs work more effectively. This is one area where much medical research has been
done, so in principle the medical results and the mathem atical models can be closely
compared to improve our understanding of how the various growth factors may affect
the use of chemotherapeutic drugs on cancerous tissue. The pulsed model clearly
shows th at incorporating growth factors in AML increases the cell kill by 13%—14%,
and reduces the number of doses needed to accomplish the same results, while in
breast cancer growth factors allow larger doses of chemotherapy to be administered at
optimal periods to obtain maximal cell kill. In this case the growth factors increased
the cell kill to about 27% — a significant improvement.
One of the limitations of this model is it does not take into account varying
parameters. For example, it is known th at over tim e the chemotherapeutic doses have
more effect on the the normal tissue and less effect on the tumor mass (resistance
etc.); also the drugs reduce the carrying capacity of the normal tissue over time.
Future work will include modifying some of these assumptions, thereby formulating a
more comprehensive model. Even accepting the simplifications, this model illustrates
some of the more im portant dynamics of chemotherapy. It identifies, for example,
param eter regions of acceptable chemotherapeutic regimens, some of which reinforce
regimens already developed empirically, and also it indicates the effects of the drugs
on normal tissue and how this affects the chemotherapeutic process. The model also
identifies how the use of growth factors increases the effectiveness of the drugs, again
51
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reinforcing much of the clinical work done in the area of cancer chemotherapy.
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C hapter 4
N on -C on stan t P aram eters

4.1

In trod u ction

Though the models in the past two chapters reveal some interesting and useful in
sights into chemotherapy, many simplifying assumptions were made. In this chapter,
by allowing various parameters to vary, we can remove some of those assumptions,
thus creating, it is hoped, a more accurate model.
One of the most commonly known phenomena of tum or growth is th e ability to
m anipulate the host environment. W ithout stressing the biological mechanics, let
us try and gain some basic mathematical insights into the problem. Michelson and
Leith discuss the need for non-constant parameters to accurately model the growth
of the tumor. In their papers, [48, 49, 51], they state th at parameters such as “K”
(the carrying capacity) or “r” (the growth rate) should vary with respect to tim e
due to various tum or effects such as the tum or bed effect (TBE) and growth factor
signal processing. Also, Michelson and Leith [52] discuss how non-constant “K” and
53
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“r” may be used to show the interplay between a liver tumor and the liver. In this
case the parameters are functions of one or both of the cell masses.
A more realistic method (as opposed to pulsed therapy) to model the effects of a
chemotherapeutic drug is to vary the growth rate of the cell population. This is done
in a periodic fashion to represent periodic chemotherapy. The models developed give
rise to systems of periodic differential equations and many of the existing methods
of analyzing these solutions (such as Floquet theory and the averaging method) may
be used here.
We will first investigate a homogeneous model, i.e. one th at describes ju st one
type of cell mass, using the logistic growth model. Once we have developed a good
basis with the homogeneous logistic model, we can study the impact of piecewisecontinuous periodic parameters on the heterogeneous cell-specific models. In this
process we can develop a more sophisticated model and also discuss whether these
modifications produce any new results or if they are qualitatively similar to the
(mathematically simpler) model of pulsed therapy.

4.2

N on -C on stan t “K ”

Because the tumor, through the use of growth factors etc., can manipulate its local
environment, a constant carrying capacity, “K”, can n o t accurately model growth
of the tum or mass. To better model the growth of the tum or we allow “K” to be a
non-constant function of the tumor mass. First investigate the Logistic equation:
— = r V ( l ------— 1.
dt
^
K(V)J

(4.2.1)
K
]
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The basic assumptions on K ( V ) axe:
1. K ( V ) is monotone increasing
2. K { V ) is bounded by 0 < K min < K ( V ) < K sat

3. K { V ) = V has a solution. This can. be shown to be a consequence of (1.) and
( 20 -

First, note the existence of V*, where V* is a solution to K ( V ) = V. Because of
the above conditions on K ( V ) , it can be shown th at K ' ( V ) —> 0 as V —> oo. This is
true because K ( V ) is monotone increasing and bounded. Since ^ = 1 then K ( V )
must cross V at least once because K ( V ) > 0.
Now, look at the stability of V*. Linearize (4.2.1) about V* to get:

Vt = - r ( l + K v (V*))Vi.

It can be seen th at

(4.2.2) is

(4.2.2)

stable provided Ky(V*) > —1.Since it is assumed th at

K ( V ) is monotone increasing then this condition is always true.
Next, the steady state V* is shown to be in the interval 0 < K min < K* < K sat.
This can be shown

by differential inequalities. Note that:

= r y (1 - S M ) < r V (1 - £ )
v '

=

r V (1 - W

) ) ^ r V (1 - £

<4-2-3>

r)

therefore K min < V* < K aat.
Similar results can be shown for the competition system of equations.
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(4-2-4>

4.3

P iecew ise H om ogeneous M od el

The logistic growth model has been used in many cases as a basic model of both cell
growth and more particularly tumor cell growth (Eisen [23], Swan [63], Michelson et
al. [53] and Michelson and Leith [48, 51]). There are various methods of modeling the
effects of chemotherapy within the logistic model. One of the easiest is to assume th at
the drug kills cells instantly, thus giving a pulsing type action. This type of model is
investigated by Berenbaum [7], and in chapters 2 and 3. A more realistic method of
modeling chemotherapy is to assume th at the chemotherapeutic effects are modeled
by continuous or piecewise-continuous periodic functions which affect the growth
rate (i.e. non-constant parameters) in the logistic growth model (Michelson and
Leith [51]). These periodic functions alternate the growth rate between a negative
rate when the drug is present and a positive rate during the recovery stage. This
is the method investigated in the present chapter. Because of the availability of
closed form solutions to the logistic equation, this chemotherapeutic problem can
be handled with analytical methods. Numerical solutions to this model have been
used in P anetta and Adam [57] to model the effects of the chemotherapy on bone
marrow. A similar model is discussed by Hallam and Clark [36] which describes a
deteriorating environment through the use of decreasing growth rates and carrying
capacities, and by Coleman et al. [15] who investigate positive periodic growth rates
and carrying capacities. The model in this chapter investigates periodic forms of the
growth rate param eter by allowing this growth rate to be negative to more effectively
model periodic chemotherapy.
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4.3.1

The M odel

The logistic growth model is modified to include a variable growth rate, thus mim
icking the effects of chemotherapy. The general form is:
^

= r,W ( [ l - W l - f )

(4.3.5)

where y(t) is th e cell mass, r is the growth rate, K is the carrying capacity, and b(t)
is a periodic function representing the chemotherapeutic effects on the cell mass. If
b(t) = 0 then there are no chemotherapeutic effects and the equilibrium is K , while
if b(t) = b < 1 then the equilibrium is (1 — b)K. Conversely if b(t) = b > 1 then
the equilibrium is 0. If the term [1 — b(t)] is positive for all t then there is tum or
growth with a reduced growth rate and there will be an equilibrium between zero
and K . Conversely, if [1 —b(t)] is negative for some range of t then there are regions
of negative growth or cell kill, and thus the possibility for a zero equilibrium. The
object of this model isto determine conditions on b(t) such th at the equilibrium of
equation (4.3.5) is zero. To reduce the problem to a simplerform, we scale equation
(4.3.5) by writing y(t) — Kx{t). The resulting equation is:
= rx{t){[ 1 - b{t)} - x{t)).
The function b(t) can take on various periodic forms (with period

(4.3.6)
t),

including the

step type function of the form:

(

b,

nr < t < a + n r
(4.3.7)

0,

a + nr < t < (n + 1 ) t

the exponentially decaying piecewise periodic function:
b(t) = bea(t~nr\

n r < t < ( n + l) r ,
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(4.3.8)

Figure 4.1: Step Function
or the modified exponentially decaying piecewise periodic function:

b{t) = b (ea<1- BT>-

, n r < i < (n + l) r .

(4.3.9)

See figures (4.1, 4.2, 4.3).

4.3.2

Solutions

There axe vaxious methods of solving equation (4.3.6) for specific cases of b(t), but
in general the equation is of Bernoulli type and can be solved exactly. The solution
is:
Xner f
1+

‘ (1~ i ^

d3

(4'3' 10)

Using this solution and the fact th at b(t) is periodic, we can set up a difference
equation (sometimes referred to as a first return map or Poincare map), th a t describes
th e state of the cells at the beginning of each period. Equation (4.3.10) describes
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the growth of the tissue over each period, where x Qis the cell mass at the beginning
of the period. The resulting difference equation is:
oT

<r>
-

( 1 —b(s))ds

nr

S^ +1)T

1+

5 m .

(A

Q -l -| \

J^ +1)Ter/* (1-6^))‘^ds'

Of interest is the stable equilibrium of this difference equation. Solving the equation
for x eq we find
rC"+Dr(
X . ae Jnr
X eq

—

'

( )
>•

>•

1 + Ssl /Oj+iK erf ^ 1- i^ d s ’
r

Jnr

(4.3.12)

and hence we can determine the equilibria. They axe:
=

33 e g

0

(4.3.13)

r ^er /^r+1)r(1- 6W)ds- 1^
23eg

—

/(*+!)* er f 3 (i-b((Mds '

(4.3.14)

Next, we define:
(b(t)) = - [ Tb(t)dt.
r Jo

(4.3.15)

as the mean value of b(t). Equation (4.3.14) is equal to zero for (b(t)) = 1, which
is the bifurcation from a positive stable equilibrium to a zero stable equilibrium.
T hat is, for 0 < (b(t)) < 1 equilibrium (4.3.14) is stable and equilibrium (4.3.13)
is unstable. For (b(t)) > 1 the stability switches and equilibrium (4.3.13) becomes
stable while equilibrium (4.3.14) switches to unstable. Therefore th e cells have a
zero equilibrium when
(&(<)) > 1.

4.3.3

(4.3.16)

Step Function

We can examine the special case of the step function form of b(t)(equation (4.3.7))
directly by examining the solution over each piece of the period r . First we find the
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solution in the region nr < t < a + nr, and then m atch it to the solution in region
a + n r < t < (n + l) r . Thus we obtain:

x(t) =

(1 —b)xnT
U-a-Hrd-nr)
Xnr + [(1 - b) - Xnr\e~(1~h)T(t- nr)
®(a+rar)

---------------------------- —
a to + n r ) + [1 -

a (o + « r ) ] e - r (t-ta+»«-))

TIT < t < 0, + TIT
.

(4.3.17)

a + n r < t < (n + l ) r
“

V

1

Matching the two solutions at a + n r we find:

® (a+nr) —

(1 - b)xT
Xnr + [(1 - b) - x^je-C 1- 6)0

(4.3.18)

Prom this solution a difference equation can be found th a t relates the size of x{t) at
the beginning of one period (xnT) to th a t of the next period (x(n+1)T). The Poincare
map for equations (4.3.17) is:

a ( n + l) r —

1+

'x nr +

[(1

- b) - x nT]e ft i)gr _ '
(1 - b)xnr

(4.3.19)
g -r (r -a )

The equilibria for this difference equation are:

(4.3.20)
I _ e r(a 6 -r)

Xeq —

1 - j4+(e-“r(1_6) - &)e-r(T-“)

(4.3.21)

This is just a special case of equations (4.3.13) and (4.3.14) where the bifurcation
from equilibrium (4.3.21) being stable to equilibrium (4.3.20) being stable is ab = r.
(Note th at this is the same result as (b(t)) = 1.) Figure (4.4) shows the bifurcation
diagram distinguishing between the stable and unstable equilibria.
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Figure 4.4: Bifurcation Diagram, a = 3, r = 6, r = l
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3

4.4

P iecew ise C ell-Specific M od el

For the piecewise continuous cell-specific case, model (3.2.2) will be modified as:
I
dx
dt

(

\
—a

/3
x—

\
g(t) o
X.

o

■0

(4.4.22)

o

The function g(t) is a piecewise continuous function describing the chemotherapeutic
effects on the tumor. Webb studies a similar model in his study [66], where he uses a
step function to model the chemotherapeutic effects. We will investigate the model
using the exponential decay function, (figure (4.2)):

g(t) = he 'd*-riT)) n r < i < (n + l) r ,

(4.4.23)

where h is the cell kill param eter and 7 is the decay of the drug. However as seen
in Webb [67, 66] and in the previous sections, g(t) may take on many other forms
as considered appropriate. In this section, we will compare the results of this more
realistic model of chemotherapy with the more mathematically tractable pulsedtherapy model.

4.4.1

Norm al Tissue

For the piecewise case the limited growth equation for normal tissue is:

y=

6

( K — y) — he

nT\

n r < t < (n + l)r.

(4.4.24)

Finally, the logistic form for the piecewise case is:

y = Sy( 1 - ^ ) - h e 7(i nr)y, n r < t < {n + l)r.

(4.4.25)
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See section §4.3. In equations (4.4.24, 4.4.25)

8

is the growth rate of the normal

tissue and K is the carrying capacity.

4.4.2

Confluent H ypergeom etric Solutions

The model that we investigate is based on equations (4.4.22, 4.4.23) and the normal
tissue condition (4.4.25). Analytic solutions to the tum or equation can be found
in term s of confluent hypergeometric functions. In particular, we are interested in
comparing the results of the pulsed therapy with those of the piecewise therapy. This
will help us understand, in a qualitative sense, if and when the more sophisticated
model will be needed. Note th at the parameter 7 in the piecewise case describes the
decay rate of the chemotherapeutic drug. A large value of 7 (for fixed h) therefore,
corresponds to the effects of the drug decaying away quickly. This is qualitatively
equivalent to a high survival fraction, /(£>), in the pulsed case.

A nalytic Solutions
Reformulating the system of differential equations (4.4.22, 4.4.23) as a Schrodinger
equation in time, i.e.

% + (A■- V(i)) , = 0

(4.4.26)

we may investigate analytic solutions to the piecewise chemotherapeutic case. W ith
the choice of an exponentially decaying function representing the effects of chemo
therapy on proliferating tum or cells (see figure (4.2)), the potential function V(t)
in equation 4.4.26 is a Morse-type potential, well-known in the quantum mechanical
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literature (see Flugge [26]); and the solutions are obtainable in terms of confluent hy
pergeometric functions or the related W hittaker functions). Because th e chemother
apy is administered periodically, the potential V(t) is periodic also. Therefore, using
existing Floquet theory as applied to scattering by periodic potentials in the quan
tum theory of solids, we find corresponding results in our chemotherapeutic case.
More specifically, corresponding to the existence of “forbidden energy bands” in
quantum theory, it appears th at there are “forbidden” or inappropriate chemothera
peutic regimens also, in the sense th at for some combinations of period, dosage, and
cell parameters, no real solutions exist for the system of equations describing the tim e
evolutions of cancer cells in each compartment. The m athem atical details of these
analytic ideas are contained in Adam and P anetta [2] and here we will concentrate
on the numerical results of the next section.

N u m e ric a l R e su lts
Using the same param eter values as in the pulsed case with the new param eter
h = 0.5 for both the normal and tum or equations, we compare the bifurcation
diagrams of the two cases. Note the similarities between figures (4.5) and (3.4).
Both show similar regions in parameter space for acceptable period and strength.
The main difference between the two is th at in the pulsed case (which models instant
removal of cells) there is a much more dram atic change in the normal cell bifurcation
curve then in the piecewise case. This is because in the piecewise case the drugs
destroy cells over the complete period, thus there is not an instantaneous drop in
normal cell mass. Thus in the piecewise case we are not concerned about the cell
65
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Figure 4.5: Bifurcation Curves
mass instantly dropping below its critical value; consequently this model allows for
larger drug doses to be administered. Note next the similarities between figures (4.6)
and (3.5). It should be recalled th at the minimum eigenvalue means highest tumor
reduction in figure (3.5). These two graphs compare very well, both showing that
the optimal period is one that allows some tim e between doses. Finally, figure (4.7)
shows the optimal period curve along with the bifurcation curves of both normal and
cancerous tissue. A significant point to be made here is th at the optimal period curve
is completely in the acceptable region unlike the pulsed case. Therefore if we are to
compare the optimal period in the piecewise case to the regimen stated by Birkhead
et al. ( “the maximally-tolerated dose is given as frequently as the rate of bone
marrow recovery permits”), we may note th at they are basically equivalent. Thus,
if th e clinician administers a strong dose (i.e. 7 small), then the optimal period, and
the smallest period th at allows bone marrow recovery, are almost identical.
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Figure 4.7: Bifurcation Curves with Optimal Period Curve
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4.5

D iscu ssion

Some variations can be made to this model to model chemotherapy even more effec
tively. A few possibilities include varying the carrying capacity K (either increasing
or decreasing it) to model either the tum or bed effect (see Michelson and Leith
[48, 49]) or allow a decaying carrying capacity due to cytotoxic build-up (see Hallam
and Clark [36]). A further possibility is to allow cytotoxic effects to decay over each
successive period. This can arise as a result of drug resistance because the drugs
have less affect on the cells over time.
This model gives a concise and general form for the bifurcation between reduced
steady state cell survival and cell destruction. It can be the basis for studying the
chemotherapeutic effects on both cancerous cell tissue and normal cell tissue such as
bone marrow. If it is used with cancerous tissue, then condition (4.3.16) describes
the type of regimen needed to destroy the cancer cells. If it is used to model the
chemotherapeutic effects on bone marrow, we might instead look for the point where
th e equilibrium is about half the carrying capacity since this is the lim it of acceptable
bone marrow destruction.
The piecewise model of chemotherapy is the more realistic of the two studied
in this dissertation, but mathematically it is much more difficult to investigate. As
noted above, it can be solved analytically, but this is mathematically very intensive
especially when compared to the pulsed therapy case. By comparing the various
bifurcation diagrams and optimal period diagrams, we can observe th at the results
obtained numerically from the piecewise model are qualitatively very similar to those
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obtained from the pulsed case. Only a few differences are noted. Because of this,
very similar q u a lita tiv e results may be drawn from either model. Therefore in
many situations it would be wise to choose the mathematically more appropriate
model — the pulsed therapy model. However, if circumstances perm it and a more
realistic approach to the chemotherapeutic effects is desired, the piecewise model is
the better choice.
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C hapter 5
Tum or R esistan ce

5.1

In trod u ction

Resistance to cytotoxic drugs is a major cause for failure of chemotherapy (Goldie and
Coldman [29, 30] and Michelson and Leith [50]). Thus, for a more realistic approach,
the chemotherapeutic models should also incorporate the effects of resistance. Two
m ajor types of drug resistance to consider (though there are others) are: inherent
and acquired. Inherent resistance refers to tumor cells th at are resistant from the
beginning of chemotherapy. Conversely, tumor cells which are initially susceptible to
the drug, but develop resistance over time, are considered to have acquired resistance.
(We will only work with acquired resistance effects here).
The first model we investigate is an extension of the tumor-normal cell interaction
model in chapter 2. Instead of just having a tumor and normal cell compartment,
we add a resistant compartment. We continue to use pulsed therapy in this case and
define new parameter ranges of acceptable treatm ent.
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A second approach used here to model drug resistance is by means of a decaying
periodic chemotherapeutic term added to the logistic growth model (i.e. the non
constant param eter approach as opposed to the pulsed therapy). Thus, over each
period the drugs will have less and less of an effect on the cancer tissue. As can
be clearly seen, unless the drug regimen can destroy every cancer cell after a finite
number of doses (which is not possible in these models given the nature of the
differential equations being studied), no single drug will be able to control the growth
of the cancer tissue. Consequently we axe more interested in finding the appropriate
number of doses while still reducing the size of the cancer cell mass (this is known as
the nadir). Knowing the nadir can help in ascertaining when to switch to a different
drug and how to better design drug regimens.
Finally, we model resistance with a heterogeneous two compartment model; one
for sensitive cells, the other for resistant cells. Various forms for this model have been
studied. Birkhead et al. [12] discuss a linear system of equations modeling sensitive
and resistant cycling and quiescent cells. They carry out numerical experiments
with various drug-delivery methods where the drugs are assumed to be effective
instantly. Gyori et al. [34] investigate a non-linear two-compartment model where
sensitive cells m utate to resistant cells, both as a result of the cytotoxic drugs and by
spontaneous mutation. They study analytically the effects of one drug dose on the
system and study numerically the full system. P anetta [56] studied a model similar
to th at of Gyori et al. but the chemotherapeutic effects are modeled by periodic
instantaneous cell kill or pulsing. In this chapter we derive a model similar to these
and include piecewise-continuous and continuous instantaneous chemotherapeutic
71
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effects. Analytic results describing the bifurcation between tum or growth and decay
axe developed.
The models in these sections are compared to some clinical results on chemotherapy given by Skipper [60].

5.2

P u lsed M odels

If a resistant subpopulation occurs (i.e. 100% resistant), then the tum or can never be
killed off unless the drugs axe altered to have an effect on the most resistant popula
tion. This will entail the use of non-cross-resistant drugs. Models th at assume 100%
resistant cells axe discussed by Goldie and Coldman [29]. They show, by stochastic
methods, th at as the tumor burden is increased there is a higher probability of the
tum or becoming resistant, and that there is a small critical tim e interval in which
the probability of the tumor developing resistance goes from low to high.
Resistance may arise in various ways. One such way concerns resistance th at
is n o t induced by the applied drugs. Since tum or heterogeneity is common (see
Michelson et al. [50]), this is a very common situation. This will be modeled by a
continuous flow of cells, independent of the chemotherapy, from sensitive to resistant
compartments. The other type of resistance is induced by the drugs; th a t is, as the
drugs are administered, some sensitive cells become resistant. This could be caused
for example by genetic mutations. This will be modeled by a discrete flow of cells,
dependent on the chemotherapy, from sensitive to resistant.
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5.2.1

Acquired Resistance: Cell M utations

M artin et al. [44] state that some types of drug resistant cells arise at a constant rate
and are n o t induced by the chemotherapeutic drugs. This gives way to heteroge
neous tumors. Michelson et al. [46, 53] have developed heterogeneous tum or models
without normal cell interaction or chemotherapy, and Gyori et al. [34], using the
model developed by Michelson et al., add the effects of a time-dependent cytotoxic
agent. These models can be a modified in the following way to account for normal
cell interaction and periodically-pulsed therapy: thus we write
dX_
dt
dY\
dt
dY 2
dt

y2(nr+ ) =

r1 X ( l - X / K

- X 1 (Y1 + Y2))

(5.2.1)

r 2 Yx( 1 - (Y1 + Y2 ) / K 2 - X2( X + Y2)) - m Y 1

(5.2.2)

rzY2{1 - (Yx + Y2 ) / K 2 - X3( X + Yx)) + mYx

(5.2.3)

F(D)X(n T~ )

(5.2.4)

F(D)Yx(nT~)

(5.2.5)

F(D)Y 2 (nr~)

(5.2.6)

1

where X is the normal cell biomass, Yx is the sensitive tum or cell biomass, Y 2 is the
resistant tum or cell biomass, and m is the resistance parameter. Usually m is very
small since cancer cells m utate at a rate of about 1 in every 106 cells (see Michelson et
al. [46]). Note th at Ai could be zero in the non-interactive case, but for the sake of
generalization, we will keep it in.
We assume th a t two drugs are administered, both affecting the sensitive cells
with survival fraction F(D), the resistant cells with survival fraction F{D) and the
normal cells with survival fraction F(D). This leads to the reasonable assumption
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F ( D ) < F(D), i.e. the drugs will have a stronger effect on the sensitive tum or cells
than the resistant tum or cells.

5.2.2

No Therapy Case

Let us first investigate the case with no chemotherapy. Michelson et al. [50] note
th a t for this model, in the constant coefficient case, there is no equilibrium where
the resistant cells, Yz, are excluded and sensitive cells, Yi, survive. B ut, with the
proper choice of parameters, the coexistent equilibrium can be driven as close to the
I 2 = 0 case as possible. They note th at in this limit, the deterministic model can
break down ( i.e. the model does not take into account small random fluctuations
th a t can have a large affect on a small cell population).
As before, the stability of the tumor free case, (A i, 0,0), is investigated and
param eter ranges for tum or growth are given. Linearizing equations (5.2.1-5.2.3)
about X = K i + eu, Yi = 0 + ev, and Y2 = 0 + ew we obtain:
I

u'

\

\ W/

/

I
—r i

\

—r iA iA i

0

r 2(l —A2A 1) — m

0

m

\

—r iA iA i

u

0

V

r 3(l - A3A 1) t

,

w

(5.2.7)
.

We investigate the stability by looking at the eigenvalues. In particular, we are
interested in the second two equations of the system. Since they decouple from
th e first equation, we may focus on them alone. The condition on sensitive cell
recurrence is A2A 1 < 1 —m/rz. This condition is more restrictive than th at of the
zero resistance case because of the presence of the m / r z term . As m increases it is
harder for the sensitive cells to recur, and as r 2 increases the sensitive cells can grow
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faster, thus making it easier for them to recur. Also, if m > r 2 then th e sensitive
cells can n o t recur, although, typically m «

r2. The condition on resistance cell

recurrence is X3 K \ < 1, although, if the sensitive cells recur, then the resistant cells
m u s t recur (see Michelson et al. [53]) even if X3 K \ > 1. This can be seen by looking
at the third equation (w 1 = m v + r 3(l —X3 Ki)w). Since v is increasing then so must
w. But if X3 K 1 < 1 and X2 K 1 > 1 —m / r 2 then the resistant cells will recur without
the sensitive cells.

5.2.3

R esistant Recurrence

As before, we investigate the effect a small tumor burden has on the tum or free
periodic solution given in § 2.3. Thus the system is linearized about (X ,(i),0 ,0 )
and the stability of the sensitive and resistant subpopulations is investigated. In the
same manner as before, we investigate the lineax system
(

\
v!

\ w /
/
r x(l -

\

-

n

A

0

r 2(l —A2X a(t)) — m

0

m

\

—ri XiX 3 (t)

u

0

V

r 3(l - X3 X a(t)) f

(5.2.8)

^. w f,

where X = X 3 (t) + eu, Y\ = 0 + ev, and I 2 = 0 + ew. In this case the second two
equations decouple and the second can be solved by integrating v' = (r2( l —X2X 3(t))—
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m)v over n r < t < (n + l) r . This gives:

[

F (D )e^-m^r

u (n + l)r — v n r ^

}
f >

( 5 .2 .9 )

I F ( D ) * ^ e^K ir )
The condition to prevent sensitive cell recurrence is:
F(D)

<

F ( D ) ' rtrn *9 * 1 e - ^

( i - A 2^ i )

( 5 .2 .1 0 )

(i.e. the survival fraction for the sensitive tumor mass is less than th e survival
fraction for the normal tissue.) Note th at we assume r 2 > > m and X2 K 1 < 1 (see
the previous section). Since m is very small, it has very little effect on th e outcome.
Thus, this condition is almost identical to equation

( 2 .4 .1 8 ) .

As in the zero-drug case, resistant cells must recur if sensitive cells do, and
there can be resistant cell survival even if the sensitive cells do not recur. To find
the condition for this, we must integrate w 1 = r3(l — X3 X s(t))w over the interval
n r < t < (n + l ) r yielding:
F(D)eT3T

{

1

raVjK,

F { D ) ' ^ e ^ K^

f •

(5 .2 .1 1 )

J

Thus the condition to prevent resistance recurrence is:
F(D)

<

F iD y^e-^V -W i)'

( 5 .2 .1 2 )

It is im portant to note th at if the resistant subpopulation goesundetected, and drugs
are administered which kill only the sensitive cells then, F(D) = 1. In this case the
resistant subpopulation will recur unless it is competitively excluded (K\X 3 > 1)
since the right-hand side of equation

(5 .2 .1 2 )

is less than one.

As before, the dose-response is chosen to be F(D) = e~aiD, F( D ) = e~a2D, and
F(D) = e~a3D respectively. Then the conditions to prevent both sensitive and
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resistant tum or recurrence while keeping the normal cells above the specified level
0 < a < 1 axe:

r r 2(l X2K \ ) __________
a 2 — ctiX2 K i(r 2 — m )/r i

I")

D

>

/ k

n

- iq \

( 5 .2 . 1 4 )

a3 - aiX3Kir3/ri
D

<

— ln (a + e -riT( l - a ) )
ai

(5.2.15)

For there to be a region of resistant recurrence without sensitive recurrence the graph
of (5.2.13) (the equality)

must be below that of (5.2.14), or the slopeof (5.2.14) with

respect to r m ust be greater than th at of (5.2.13). In general, this will depend on
the growth rates and competition parameters of the two populations along with the
dose response parameters (a;). In the special case where r 2 = r 3 and A2 = A3 (a
biologically reasonable one) the condition is 0:3 — 0:2 < aiX 2 K im /r i. If 0:3 > a 2
(F (D ) > jF(D),which is unrealistic) then, since m is very small, there will only
be a very small region where resistant cells can recur without sensitive cells. If
a 2 < a 2 (F (D ) < F (D ), typically true) then there will alw ays be a region of
resistant recurrence without sensitive recurrence. Replacing o:2>r2, X2 with 0:3, r 3, A3
in equation (2.4.21), we can see
a i r 3(l - aX3 K x)
“» >
ri(l - a ) —

f

\

P-2'16)

is th e minimum condition needed for the treatm ent to be able to prevent resistant
tum or recurrence.
Figure 5.1 gives an example of two regions of dose vs. period.

One occurs

where the tumor cannot recur and the other where only resistant tum or cells can
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Figure 5.1: Dose-Response Curves: Dose vs. Period
do so. The upper line refers to equation (5.2.14) (the equality); the lower line refers
to equation (5.2.13), and the curve is equation (5.2.15). From this graph we can
see how the two regions are close together, thus showing how sensitive the results
are to small changes in dose or period. Additionally, if the resistant population is
undetected, then we can easily choose a dose and period to eliminate the tum or
which actually falls in the range of resistant recurrence. Thus the tum or can recur
even though it appears th at we are administering an acceptable dose regimen.

5.2.4

Induced R esistance

Birkhead and Gregory [9] and M artin et al. [44] note th at tum or cells can m utate or
transition to resistant subpopulations as a result of exposure to chemotherapeutic
drugs. W ith regard to this, a variation can be made to the above model to model
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induced resistance:

dX = riX(l - X / K i - X (Y + Y2))
—
dt
dY[
dt = r2Yx{i - (yx+ y2)/k2 - x2(x + y2))
1

m_

=

dt

r 3 Y2 ( l - { Y

1

1

+ Y 2 ) /K 2 - X 3(X + Y1))

(5.2.17)
(5.2.18)
(5.2.19)

X ( n r +) =

F {D )X (n r~ )

(5.2.20)

F i(n r+) =

(F (D ) - R(D ))Yi(nT~)

(5.2.21)
(5.2.22)

Y 2 (n r+) = F{D )Y 2 {nT~) + R{D )Yi(nT~)

where in equations (5.2.21, 5.2.22) R (D ) is the fraction of cells becoming resistant or
induced due to the dose of the drug. Note th at R(D ) can be a function of drug dose
and in some cases could be as large as 0.5 (i.e. 50% of the surviving cells become
resistant).

Norm al Growth
As in §2.3, we are interested in the stability of the tumor free case, (A i, 0,0). Lin
earizing (5.2.17, 5.2.18, 5.2.19) about the tumor free state (X = K i + eu, Y\ = 0 + ev,
and Y2 = 0 + ew) we obtain:
(

\

{

v!

w

\

—r i

—\ir\Ki

—XiriKi

0

r 2(l —X2K \ )

0

0

0

rs(l — X3K-\)

\ (

\
u
(5.2.23)

\ w 1

Note th at this has similar conditions for recurrence as equation (2.3.5). T hat is, the
sensitive cells will recur if X2K \ < 1 and the resistant cells will recur if X3K \ < 1. For
this problem however, unlike the previous case, we can have sensitive cell recurrence
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without resistant recurrence and the recurrence of one does not affect the other. It
merely depends upon the competition coefficient A,-. Thus prior to therapy, sensitive
cell recurrence has no effect on the recurrence of resistant cells.

In d u c e d R e s ista n c e w ith C h e m o th e ra p y
Continuing with the same approach as before we linearize the system about the
tum or free periodic solution (X s(t), 0,0). In this case we will solve the two decoupled
equations, v' = r 2(l —A2X ,(t))u and w' — r3(l —A3 X 3 (t))w, by integrating over the
period and applying the pulsing conditions (5.2.21) and (5.2.22). This gives us the
system of difference equations:

(n+l)T —

\ (F(D ) - R(D ))e™ 1
nT 1
r2A2K,
f
{ F { D ) ^ ^ e r^ K ^

..
w (n + l)r

—

f

v nr S

R(D )e™

\ ,

,-2 *2 * !

(5.2.24)

J

I

f d" w nr 1

F (D )e'”
ra^ x,

} ,r „
f (5.2.25)

Now we examine the stability of this system. Note th at the sensitive tum or cells
c a n n o t recur if:
F{D) < F {D ):*%rLe -TT2(1- X2Kl'>+ R(D ).

(5.2.26)

Note also th a t R{D ) increases the size of the right-hand side, thus making it easier to
prevent sensitive cell recurrence. Depending on the size of R(D ), it will have varying
affects on the outcome. Larger R(D ) (near 0.5) will make it vary easy to prevent
sensitive cell recurrence while smaller R(D ) will have a minimal affect. Secondly,
if the sensitive cells recur then the resistant cells will also recur because the second
term on th e right-hand side of equation (5.2.25) will grow in spite of the first term .
Thus resistant tum or population recurrence does not depend on competitive pressure
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if there is sensitive recurrence and continued dosing. But, sensitive cells recurring
w ithout continued dosing does not imply resistant recurrence. Finally the resistant
tum or cells can recur even if the sensitive cells do not, provided that:

F (D ) > F (D ):2 ^ e - TT^ 1- X3Kl\

(5.2.27)

This result is derived assuming th at there are sensitive cells initially, which is very
likely. Note th a t this result is consistent with condition (5.2.12) for non-induced
resistance.

5.3

P iecew ise-C on tin u ou s M od els

Now, we study various ways to model drug induced resistance with piecewise-continuous chemotherapy.

5.3.1

H omogeneous Tumor

We model cancer cell growth with resistance by exponential growth instead of logistic
growth. This is an acceptable simplifying assumption, since the carrying capacity
for most cancerous tissue is much larger then the maximum tum or mass th a t the
host can withstand. Thus exponential growth is an acceptable approximation to the
growth between each period of treatm ent.
The model for decaying drug effects, most likely caused by th e development of
resistance to the drug, is:

= r (* ~ ^ T + l )

nT - f < (n + 1)T

(5.3.28)
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where 7 is the resistance parameter and n is an integer which represents the number of
the dose th at is being delivered. Large 7 represents cells rapidly becoming resistant to
the drug and small 7 represents cells switching to resistance more slowly. To find the
nadir we need to determine when X(„+i)T > x nr. This condition can be investigated
by studying the the first return map of equation (5.3.28). This difference equation
is:
z(n+i)r = xnTerT(1- $ $ ) ,

(5.3.29)

or in terms of the initial value xq\
X(n+i)T = x o e ^ ” f t erT(1-^ ) .

(5.3.30)

t= 0

Solving aj(n+i)r

x nr the condition on the number of doses th at may be given before

the cell mass will start to regrow instead of decline is:
”■> i ( W ) ) - !)•

(5.3.31)

(See figure (5.2).) A more direct way of establishing the nadir is to just view the
characteristic exponent of the first return map (5.3.29). When this is greater than
or equal to zero the same condition for the nadir as above is obtained.
For a basic model of resistance, this fits very well to actual d ata given in Skipper
[60]. Compare figure (5.3) with graphs of data in Skipper.

5.3.2

H eterogeneous Tumor

The general heterogeneous tumor model used is similar to th at of Gyori et el. [34].
It is of the form:
x' =

n x ( l - x /K i - ciy) - (b0 do(t) + bidi(t))x

(5.3.32)
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Figure 5.2: NADIR, Homogeneous Case
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Figure 5.3: Tumor Mass vs. Time, Homogeneous Case

83

R eproduced w ith perm ission o f the copyright owner. Further reproduction prohibited w itho ut perm ission.

y' =

b0 d0 (t)x + r 2 y( 1 — y /K 2 — c2 x) - b2 d2 (t)y,

(5.3.33)

where x represents the sensitive cell mass and y represents the resistant cell mass.
The various parameters are as follows: bo represents the induction rate of cell trans
formation (i.e. the rate at which they move from the sensitive to resistant compart
ments due to cytotoxic drugs), &i represents the effects of a cytotoxic drug th at only
affects the sensitive cells, b2 represents the effects of a cytotoxic drug th a t can also
affect the resistant cells, do,i(t) are periodic functions of period T\, d2 (t) is a periodic
function of period t 2 (these represent the periodic behavior of the chemotherapy),
and th e rest of the parameters are the regular parameters in a competition model.
The induction rate of sensitive cells can range from almost zero to nearly 50% of
surviving sensitive cells becoming resistant per dose.

5.3.3

Linear M odel

As in the previous section we will eliminate the non-linear terms from equations
(5.3.32, 5.3.33) for the following reasons, (i), The carrying capacity (K i) of most
tumors is much larger then the host can sustain; (ii) the drugs periodically destroy
tum or mass keeping the tumor far from its carrying capacity (if the drugs do no do
this the host will die); (iii) chemotherapy is often used in the adjuvant setting (post
surgery) when the tumor burden is relatively low or to treat a m etastatic burden;
(iv) the linear system is much easier to handle analytically. Therefore, eliminating
the non-linear terms from equations (5.3.32, 5.3.33) we obtain:

x' =

( n —(bo + bi)d0 (t))x

(5.3.34)
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y' =

b0 d0 (t)x + (r 2 —b2 d2 (t))y.

(5.3.35)

Note th a t equation (5.3.34) is decoupled from equation (5.3.35), therefore we can just
examine equation (5.3.34) and determine separately the dynamics of th e resistant
compartment (equation (5.3.35)). Because of the possibility of different periods for
the two drugs, we define the mean value function to be:

(/« > * = - / " / « * .

i = 1 .2 .

(5.3.36)

T i JO

Note th a t the following is a useful relationship between the two means:

mu =%
«>*•
T2

(5.3.37)

By integrating equation (5.3.34) over period T\ we get the condition required to
destroy the sensitive cells. This condition is:

(6° + 6 l ) n ( d o ( t ) ) Tl > 1.

ri

(5.3.38)

If this condition holds (which it m ust if the therapy is to come even close to affecting
the tum or), then the steady state effects of the resistant compartment can be studied
by examining equation (5.3.35) with x = 0. Therefore the condition th a t will also
destroy the sensitive cells can be found by integrating equation (5.3.35) with x = 0.
This results in the condition:
- r 2 (d2 (t ) ) T 2 > 1.
r2

(5.3.39)

Thus to have an effective drug regimen we need both condition (5.3.38) and (5.3.39)
to be valid. Note th a t these conditions hold for both th e linear model and the full
non-linear model.
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Figure 5.4: Tumor Mass vs. Time, Heterogeneous Case, Step Function
The following graphs give a cleaxer indication of how conditions (5.3.38) and
(5.3.39) affect the growth of the cancer cells. It is assumed th a t condition (5.3.38)
holds in all cases; thus we axe interested in the bifurcation to resistant emergence.
The most interesting feature of these graphs is that they qualitatively m atch actual
studies of chemotherapeutic regimens listed in Skipper [60]. Although this model is
only a lineax version of a more realistic model, it nevertheless qualitatively fits the
clinical results. Figure (5.4) shows an acceptable regimen of drugs, while figure (5.5)
gives an unacceptable regimen. In both of these a step function (see figure (4.1))
is used to model the effects of the drug.

In the case of th e modified exponential

function (see figure (4.3)), an unacceptable regimen has th e form of figure (5.6).
In many cases (as noted above and by Skipper [60]), condition (5.3.39) will not
hold, and hence the resistant cells will eventually take over, unless another drug
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Figure 5.6: Tumor Mass vs. Time, Heterogeneous Case, Modified Exp. Function
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Figure 5.7: NADIR, linear model: r = 18, &i = 1.475 (left graph) and b\ = 1.75
(right graph)
regimen is used that is more effective on the resistant cells. It is therefore im portant
to know how many doses will have a positive effect on reducing th e tumor mass. In
this model the nadir will occur when:

^

= 1.

(5.3.40)

At this point the total cell mass (sensitive plus resistant) will start to increase. An
example of the nadir for fixed b\ and varying Z>2 in equations (5.3.34, 5.3.35) is given
in figure (5.7). Also, comparing what happens when the period is varied with fixed
hi we get figure(5.8).

5.3.4

Non-Linear M odel

To investigate the full model (equations (5.3.32, 5.3.33)), first let us study the
constant parameter case, i.e.

d{(t) = 1. This model has already been studied
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in detail by Michelson et al. [53, 46]. There are three equilibria;
Ei

E0

= (0,0),

= (0, (r 2 —b2 )K 2 / r 2), and E 2 = (xe, ye), where E 2 is the positive solution to

(5.3.32,5.3.33) (see Michelson et al. [46]). Linearizing Eo, stability occurs provided:
r!

<

and r 2

<

60 + 61

(5.3.41)

62

(5.3.42)

are both true. Note th at conditions (5.3.38) and (5.3.39) reduce to these in the
constant param eter case. If Eo is unstable then either E i or E 2 will be stable. By
linearizing about E \ the condition for stability is:
( n - (b0 + 6j)) < -V ^ - ( r
r2

2

- b2),

(5.3.43)

and if this is not satisfied and E 0 is unstable, then E 2 is stable. (See Michelson et
al. [53] for further details.)
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Assuming th a t di(t) is a non-constant periodic function of period r , there exists
a positive periodic solution of the equation for y, namely:

y' = r 2y( 1 - y /K 2) - b2d 2( t ) y

(5.3.44)

provided (d2 (t)) < r 2 /(rb 2) (see §(4.3)). Call the solution Fi(t). Note th a t this solu
tion can be found analytically since this equation is in the form of a Bernoulli equa
tion (see equation (4.3.10). Therefore (0 ,ii(t)) is a periodic solution to equations
(5.3.32, 5.3.33). The stability may be studied in a manner similar to the constant
coefficient case by linearizing about the equilibrium. In this case, the equilibrium E\
is th e periodic solution (0 ,ii(t)), and the variational m atrix is:
r i( l - ciYi(i)) - (b0 + &i)d0(i)

0
(5.3.45)

^

b0 d0 (t) - r 2 c2 Yi(t)

r2(l - 2Yx(t)/ K 2) - b2 d2 (t) j

Since this is an uncoupled linear system, only an integration is required to find the
condition for stability of (0,ix(i)). These stability conditions are:

ri - T(b0 (d0 (t)) + &i(di(t)))
r 2 - b 2T ( d 2( t ) )

< ric ir(y i(t))

(5.3.46)

<

(5.3.47)

li2

Note th a t this reduces to the conditions in the constant parameter case when d;(f)
are constant.
Finally, it can be shown that if E q and (0, Fi(i)) are unstable, then a periodic
solution of the form (X c(t),Y c(t)) exist.
Let us again assume th a t condition (5.3.39) does n o t hold. Do the non-linear
effects modify the bifurcation significantly or is it qualitatively the same as in the
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Figure 5.9: NADIR, non-linear model: bi = 1.475 (left graph), W = 1.75 (right
graph), ci = 0.01 and C2 = 0.01
linear case? If condition (5.3.38) holds, then the equilibrium (0,F i(t)) is stable,
otherwise, there is the possibility of a periodic coexistent solution.

But, unlike

the linear case, if condition (5.3.38) does n o t hold there is still th e possibility of
destroying the sensitive cells if the right hand side of condition (5.3.46) is large
enough.

In other words, either ci is larger (resistant cells more competitive) or

T(Yi(t)) is larger. Thus there exists the possibility of reducing the sensitive cells
without administering such a large dose of chemotherapy.
More importantly, how do the non-linear terms affect the nadir? Using the same
param eter ranges as in the linear case, the nadir is plotted vs. various parameters (see
figure (5.9)). As can be seen, comparing graphs (5.7) and (5.9) we get qualitatively
th e same shape, but the non-linear form allows for higher nadir. Now, varying
th e competition param eter ci and C2 in figure (5.10) shows how the competition
parameters affects the nadir.
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5.4

C onclusions

These models give a concise and general form for the bifurcation between reduced
steady state cell survival, unlimited growth and cell destruction. It is hoped th a t
they will provide cancer researchers with better qualitative ideas on how to optimize
various clinical trials.
The model is inappropriate if the tumor develops resistance th a t is untreatable
(i.e. no drug affects it). But if non-cross-resistant drugs are administered then it is
still possible to continue to prevent tumor recurrence. One simplistic way to model
this problem is to define the drugs to be a non-cross-resistant conglomeration: th a t is
they are administered having survival fractions F (D ) and F (D ). However, because
this does not provide any insight into the mechanism of resistant recurrence, or how
to control it, more sophisticated resistance models are needed.
Since most tumors are known to be heterogeneous and heterogeneity can result
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in resistant subpopulations, heterogeneous tum or models are appropriate systems in
which to study drug resistance. Two different types of resistance axe investigated:
drug induced and non-induced. One of the main differences between these situations
arises in the zero therapy cases. T hat is, in the drug-induced no therapy case, growth
of the sensitive cell population does not affect th a t of the resistant cell population
while in the other case it does. When chemotherapy is added, both systems show
a definite region of resistant recurrence with no sensitive recurrence. This region
is im portant to identify in th at it can be avoided when planning a regimen, thus
not causing the tumor to become totally resistant (and thus killing the host). In
both cases, it is seen that the cell mutations have a very small effect on th e sensitive
cell recurrence conditions, changing them only minimally. Again in both of these
cases, the parameter region in which recurrence is prevented is generally smaller
than in the homogeneous case, since the resistant cells axe affected by fewer drugs.
One of the most im portant points to note is th a t in all cases there axe definite
regions where the therapy will either succeed or fail. This should emphasize the
importance of correct administration of chemotherapeutic drugs. Also, as pointed
out earlier, it is im portant to account for the resistant subpopulation since it can
narrow the acceptable region of drug treatm ent significantly. The main m athem atical
difference between these two resistance models is th a t the induced model has discrete
induction events and the non-induced model has continuous induction. As we have
demonstrated, these mathematical differences lead to only minimal differences in
results.
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C hapter 6
C onclusions
The need for mathematical models of chemotherapy is becoming more clear. As
stated by Skipper [60],
Over 20 years of experimental and clinical experience has demonstrated
th a t intuitive or triai-and-error manipulations of doses, schedules, and
combination of drugs—without guidance as to the elfects of each man
ipulation—are apt to provide little or no improvement in combination
chemotherapy designs.
The models developed in this dissertation give an uniquely different approach to
discussing chemotherapeutic drug regimens. All the models show, in param eter
space, proper and improper chemotherapeutic drug regimens in terms of dose and
period, along with the bifurcation between these regimens. Some of the models verify
th a t existing clinical regimens are a “good” way to deliver drugs while other results
suggest th a t there could be other methods th at may work better. All these models
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are developed from the qualitative point of view. That is to say, we are not designing
specific drug regimens, but rather defining general criteria to guide clinicians to more
effective treatm ent schedules. In addition since one of the m ajor limiting factors of a
drug regimen is the negative effects on various normal tissues such as bone marrow,
a constraint equation representing these effects is incorporated. This allows us to
discuss delivery of proper regimens without them overly destroying normal tissue.
The first model described in Chapter 2 investigates the possible interaction be
tween cancerous and normal tissue. Though this is not the case in all cancers, some
examples of where this interaction may possibly occur were given, including the im
mune system or the liver. By using the pulsed therapy on a small metastisized tum or
mass, we were able to develop parameter ranges of acceptable dose and period while
preventing the over-destruction of the normal tissue.
The model in Chapter 3 discusses cell-specific chemotherapy. The most interest
ing result from this chapter is that fact that we actually want to have a gap between
periods of drugs (which may seem counter-intuitive) to allow cells to “move” to the
proliferating compartment. This model uses various known results from Floquet
theory to help determine criteria such as the optimal period (i.e. the period which
gives the largest cancer mass reduction per dose).
There have also been many medical advances in the use of HGF’s to enhance the
effectiveness of the chemotherapeutic drugs. By varying the parameters which relate
to th e effects of the HGF’s, such as the growth rate of the bone marrow (rate of
leukocyte production) or the transition rate from resting to cycling cells, the model
in this chapter is extended to describe the dynamics of these HGF’s. In fact this
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particular model confirms what recent clinical results have shown, namely th a t the
growth factors can increase the effectiveness of the chemotherapeutic drugs rather
significantly.
Chapter 4 extends the idea of varying the parameters to better model the effects
of chemotherapy. By means of a simple model of logistic growth with an increasing
“K”, the carrying capacity of the host for the tumor, we can observe how the tum ors’
ability to manipulate its environment can lead to uncontrolled growth. This can
be related to the experiments with the tum or and the mouse, where the tum or is
able to grow so large that it is as big as the mouse. This idea and the need for
non-constant parameters is a continuing area of much research. This includes a
recent publication by Michelson and Leith [52]. As described in this dissertation and
in many publications, this area is extremely important in describing many of the
interactions between various cells in cancer.
Other variations on the parameters were done by varying the growth rate of the
cancer, which can also represent the effects of the chemotherapeutic drugs. Here
bifurcation conditions were developed, again in terms of the dose and period, th at
identify regions of growth or decay. In the heterogeneous case, we were able to
find analytic solutions of the equations to be in the form Confluent Hypergeomet
ric functions. Also, using ideas from quantum mechanics we developed criteria for
acceptable and unacceptable chemotherapeutic regions.
Chapter 5 covered one of the most im portant issues in developing chemotherapeu
tic regimens, namely drug resistance. The models developed in this chapter describe
various ways of mathematically explaining drug resistance. Each of these models
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fits well qualitatively with results discussed in Skipper [60]. These models identify
im portant results such as how many doses may be given before resistance “takes
over” and acceptable methods of delivering combination chemotherapy th a t control
resistance. From this type of information, clinicians will better know how to deliver
combinations of drugs more effectively to combat the effects of drug resistance.
There axe many ways these models can be extended to more accurately model the
chemotherapeutic effects. Some are for example: more accurate models of the im
mune system can be developed (i.e. take into better account their specific biological
processes), more descriptive models of the cell-cycle can be used, more information
on the mechanics of the (HGF’s) can be discussed, more extensive analysis of the
piecewise-continuous model can be investigated, and drug resistance may be added
to all the models. It is the hope that the models in this dissertation along w ith some
future development of these ideas will provide both mathematicians and clinicians
a better view of how chemotherapeutic drug regimens work in theory and how to
develop more effective drug regimens in the light of these results.
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